ClinicalTrials.gg
CompletedNCT03639311Updated Jun 11, 2024Results posted

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

A Phase 2 interventional study of CAB LA and RPV LA in HIV Infections, sponsored by ViiV Healthcare. Completed at 30 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-11.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
97
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Enrollment
23rd of 36
97 · median 200
Started
2018
the only one that year
Phase 2
8 of 36
none open now
Registered
17th of 36
by date
Lead sponsor
24 of 36
ViiV Healthcare

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 23rd largest by enrollment, is the only one that started in 2018, is one of 8 in phase 2, and was the 17th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

This study (POLAR), is designed to assess the antiviral activity and safety of CAB LA plus RPV LA, administered Q2M, in approximately 100 adult HIV-1 infected, antiretroviral therapy (ART) experienced participants. Participants will rollover from the NCT01641809 (LATTE) study, who have completed minimum duration of Week 312 and with demonstrated HIV-1 ribonucleic acid (RNA) suppression (less than [\<]50 copies (c) per milliliter [mL]), while receiving a two-drug regimen consisting of once-daily oral CAB at 30 milligram (mg) plus RPV at 25 mg. The participants will be offered the option to switch to the LA, intramuscular injections of CAB LA plus RPV LA, Q2M or the oral fixed dose combination (FDC) of dolutegravir (DTG) plus RPV, for the continued maintenance of HIV-1 RNA suppression, known as the Maintenance Phase (From Day 1 to Commercial Approval). Duration of study will vary from country to country, until regimen receives regulatory approval and becomes commercially available. The study plans to enroll approximately 100 participants. Any participant who receives at least one dose of CAB LA and/or RPV LA and discontinues the CAB LA plus RPV LA regimen for any reason will enter a 52-week Long-Term Follow-Up (LTFU) phase. Those participants must remain on suppressive highly active antiretroviral therapy (HAART) for at least 52 weeks after the last dose of CAB LA and or RPV LA.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV
  • Antiretroviral therapy
  • Maintenance
  • Long acting
  • LATTE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older (or >=19 where required by local regulatory agencies), at the time of signing the .
  • A female participant is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotrophin [hCG] test at Day 1), not lactating, and at least with one of following conditions:

    (a) Non- defined as: (i) Pre-menopausal females with one of the conditions as documented tubal ligation; Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Hysterectomy, Documented Bilateral Oophorectomy.

(ii) defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause (refer to laboratory reference ranges for confirmatory levels)]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.

(b) Reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication, throughout the study, for at least 30 days after discontinuation of all oral study medications, and for at least 52 weeks after discontinuation of CAB LA and RPV LA.

  • The investigator is responsible for ensuring that participants understand how to properly use the methods of contraception.
  • Capable of giving signed informed consent.
  • Must have been on oral CAB 30 mg plus RPV 25 mg regimen through at minimum Week 300 of the LATTE study as per LATTE protocol dosing requirements and until Day 1 of the POLAR study. Any disruptions in dosing during LATTE must be discussed with the Medical Monitor for a final determination of eligibility.
  • Plasma -1 RNA \<50 c/mL at Week 300. If participant has plasma HIV-1 RNA >= 50 c/mL at Week 300 in LATTE, a single repeat to determine eligibility may be allowed ONLY after consultation with the medical monitor.

Exclusion criteria

Exclusion Criteria:

  • During the last 6 months of participation in LATTE, consecutive (2 or more sequential) plasma -1 RNA measurements >=50 c/mL.
  • During the last 6 months of participation in LATTE, any HIV-1 RNA measurement >=200 c/mL.
  • Any evidence of a current Center for Disease Control and Prevention (CDC) Stage 3 disease [CDC, 2014], except cutaneous Kaposi's sarcoma not requiring systemic therapy.
  • Participants with moderate to severe hepatic impairment determined by classification.
  • Any pre-existing physical or mental condition (including substance use disorder) which, in the opinion of the Investigator, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
  • Participants determined by the Investigator to have a high risk of seizures, including participants with an unstable or poorly controlled seizure disorder. A participant with a prior history of seizure may be considered for enrolment if the Investigator believes the risk of seizure recurrence is low.
  • Participants who, in the investigator's judgment, pose a significant suicide risk. Participant's recent history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk.
  • Participants has a tattoo or other dermatological condition overlying the gluteus region which may interfere with interpretation of injection site reactions.
  • Evidence of virus (HBV) infection based on the results of testing for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), Hepatitis B surface antibody (anti-HBs) and HBV DNA as follows; Participants positive for HBsAg are excluded; participants negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded.
  • Asymptomatic individuals with chronic virus (HCV) infection will not be excluded, however Investigators must carefully assess if therapy specific for HCV infection is required; participants who are anticipated to require HCV treatment within 12 months must be excluded. (HCV treatment on study may be permitted, following consultation with the medical monitor).
  • Participants with HCV co-infection will be allowed entry into this study if: Liver enzymes meet entry criteria; HCV Disease has undergone appropriate work-up, and is not advanced.
  • Additional information (where available) on participants, with HCV co-infection at screening should include results from any liver , Fibroscan, ultrasound, or other fibrosis evaluation, history of cirrhosis or other decompensated liver disease, prior treatment, and timing/plan for HCV treatment.
  • In the event that recent biopsy or imaging data is not available or inconclusive, the fibrosis- 4 (Fib-4) score will be used to verify eligibility where Fib-4 score >3.25 is exclusionary; Fib-4 scores 1.45 - 3.25 requires Medical Monitor consultation where the Fibrosis 4 Score Formula: age multiplied by aspartate amino transferase () divided by multiplied by square of alanine aminotransferase (ALT).
  • Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice or cirrhosis), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment).
  • History of liver cirrhosis with or without hepatitis viral co-infection.
  • Ongoing or pancreatitis.
  • Clinically significant cardiovascular disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease.
  • Ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the participant prior to randomization.
  • Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study medication.
  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class. In addition, if heparin is used during pharmacokinetic (PK) sampling, participants with a history of sensitivity to heparin or heparin-induced thrombocytopenia must not be enrolled.
  • Current or anticipated need for chronic anti-coagulation with the exception of the use of low dose acetylsalicylic acid (less than or equal to [\<=]325 mg) or hereditary coagulation and platelet disorders such as hemophilia or Von Willebrand Disease.
  • interval (QTc (Bazett)) >450 millisecond (msec) or QTc (Bazett) >480 msec for participants with bundle branch block.
  • Any verified Grade 4 laboratory abnormality over the last 6 months in LATTE. A single repeat test is allowed to verify a result.
  • Any acute laboratory abnormality over the last 6 months in LATTE, which, in the opinion of the investigator, would preclude the participant's participation in the study of an compound.
  • ALT>=5 times (ULN) or ALT >= 3 times ULN and >= 1.5 times ULN (with >35 percent [%] direct bilirubin) over the last 6 months in LATTE.
  • Exposure to an experimental drug (with the exception of those in the LATTE study including CAB and RPV) or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to Day 1 of this study.
  • Treatment with any of the following agents within 28 days of Day 1: radiation therapy, cytotoxic chemotherapeutic agents, tuberculosis therapy with the exception of isoniazid (isonicotinylhydrazid [INH]); anti-coagulation agents.
  • Immunomodulators that alter immune responses such as chronic systemic , interleukins, or interferons.
  • Use of medications which are associated with Torsade de Pointes must be discussed with the Medical Monitor to determine eligibility.
  • Participants receiving any prohibited medication and who are unwilling or unable to switch to an alternate medication.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    CAB LA + RPV LA Q2M

    Eligible participants from LAI116482 (NCT01641809 \[LATTE\]) study who were administered oral CAB 30 milligrams (mg) plus RPV 25 mg and who successfully completed Week 300 received their first dose CAB LA (600 mg) plus RPV LA (900 mg) injections within 2 hours of the final oral dose of LATTE given on the same day. The second loading injections were administered 1 month after initial loading dose, with subsequent injections (CAB LA 600 mg + RPV LA 900 mg) occurring Q2M thereafter. Participants continued to receive the treatment until the study intervention was locally approved and commercially available. Participants who received at least one dose of CAB LA and/or RPV LA and discontinued the CAB LA + RPV LA regimen for any reason entered a 52-week long-term follow-up (LTFU) Phase.

    Drug: CAB LA · Drug: RPV LA

  • Experimental
    DTG + RPV

    Eligible participants from LAI116482 (NCT01641809 \[LATTE\]) study who were administered oral CAB 30 mg plus RPV 25 mg and who successfully completed Week 300 received their first dose of the Dolutegravir (DTG) 50 mg plus RPV 25 mg, once daily as oral regimen on Day 1 until Month 12 in the current study. These participants were not eligible for the LTFU phase.

    Drug: RPV · Drug: DTG

  • Experimental
    LTFU: CAB LA+RPV LA Q2M Group

    This group included the participants who received at least one dose of CAB LA and/or RPV LA and discontinued the CAB LA + RPV LA regimen for any reason before end of Maintenance Period. The participants entered a 52-week LTFU period.

    Drug: CAB LA · Drug: RPV LA

Interventions

  • DrugCAB LA

    Administered CAB LA (600 mg) Q2M, as intramuscular injection.

  • DrugRPV LA

    Administered RPV LA (900 mg), Q2M, as intramuscular injection.

  • DrugRPV

    Oral dose of RPV 25 mg, administered once daily from Day 1 up to Month 12

  • DrugDTG

    Oral dose of DTG 50 mg administered once daily from Day 1 up to Month 12.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-ribonucleic Acid (RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Month 12 [Maintenance Phase]

    Percentage of participants with HIV-1 RNA \>=50 c/mL as per FDA snapshot algorithm at Month 12 was assessed to demonstrate the antiviral activity of CAB LA+RPV LA Q2M and DTG + RPV regimen in HIV-1 infected antiretroviral therapy (ART) experienced participants. The HIV-1 RNA \>=50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window.

    Time frame: At Month 12 [Maintenance Phase]

Secondary outcomes

  1. Percentage of Participants With HIV-RNA <50 c/mL as Per FDA Snapshot Algorithm at Month 12 [Maintenance Phase]

    Percentage of participants with HIV-1 RNA \<50 c/mL as per FDA snapshot algorithm at Month 12 was assessed to demonstrate the antiviral activity of CAB LA+RPV LA Q2M and oral DTG + RPV regimen. The HIV-1 RNA \<50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window.

    Time frame: At Month 12 [Maintenance Phase]

  2. Number of Participants With Protocol-defined Confirmed Virologic Failure up to End of Maintenance Phase

    Confirmed virologic failure was defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 c/mL after prior suppression to \<200 c/mL.

    Time frame: Up to End of Maintenance Phase (up to Month 52 for CAB LA+RPV LA Q2M group, up to Month 12 for DTG+RPV group)

  3. Percentage of Participants With HIV-RNA >=50 c/mL as Per FDA Snapshot Algorithm Over Time for CAB LA + RPV LA Q2M Arm up to Month 12 [Maintenance Phase]

    Percentage of participants with HIV-1 RNA \>=50 c/mL as per FDA snapshot algorithm over time was assessed to demonstrate the antiviral activity of CAB LA+RPV LA Q2M regimen in HIV-1 infected ART experienced participants. The HIV-1 RNA \>=50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: At Baseline (Day 1) and at Months 2, 4, 6, 8, 10 and 12 [Maintenance Phase]

  4. Percentage of Participants With HIV-RNA >=50 c/mL as Per FDA Snapshot Algorithm Over Time for DTG + RPV up to Month 12 [Maintenance Phase]

    Percentage of participants with HIV-1 RNA \>=50 c/mL as per FDA snapshot algorithm over time was assessed to demonstrate the antiviral activity of DTG + RPV regimen in HIV-1 infected ART experienced participants. The HIV-1 RNA \>=50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: At Baseline (Day 1) and at Months 3, 6, 9 and 12 [Maintenance Phase]

  5. Absolute Values for HIV-1 RNA of CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Plasma samples were collected for quantitative analysis of HIV-1 RNA. Logarithm to base 10 (log10) values for plasma HIV-1 RNA have been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Standard Deviation (SD)=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.

    Time frame: From Baseline (Day 1) up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)

  6. Absolute Values for HIV-1 RNA of DTG + RPV Arm up to Month 12 [Maintenance Phase]

    Plasma samples were collected for quantitative analysis of HIV-1 RNA. Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. SD=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.

    Time frame: At Baseline (Day 1) and at Months 3, 6, 9 and 12 [Maintenance Phase]

  7. Change From Baseline in HIV-1 RNA for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Plasma samples were collected for quantitative analysis of HIV-1 RNA. Log 10 values for plasma HIV-1 RNA has been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline value is defined as post-dose value minus baseline value. SD=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.

    Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)

  8. Change From Baseline in HIV-1 RNA for DTG + RPV Arm up to Month 12 [Maintenance Phase]

    Plasma samples were collected for quantitative analysis of HIV-1 RNA. Log 10 values for plasma HIV-1 RNA has been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline value is defined as post-dose value minus baseline value. SD=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.

    Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  9. Absolute Values for Cluster of Differentiation 4 Plus (CD4+) for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunologic activity of CAB LA+RPV LA Q2M. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: From Baseline (Day 1) up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)

  10. Absolute Values for CD4+ for DTG + RPV Arm up to Month 12 [Maintenance Phase]

    Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunologic activity of DTG + RPV arm. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: At Baseline (Day 1) and at Months 3, 6, 9 and 12 [Maintenance Phase]

  11. Change From Baseline Values for CD4+ for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunologic activity of CAB LA+RPV LA Q2M. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline value is defined as post-dose value minus baseline value.

    Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)

  12. Change From Baseline Values for CD4+ for DTG + RPV Arm up to Month 12 [Maintenance Phase]

    Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunologic activity of DTG + RPV arm. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline value is defined as post-dose value minus baseline value.

    Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  13. Number of Participants With Non-serious Adverse Events (Non-SAEs >=5 Percent [%] Incidence) and Serious Adverse Events (SAEs) for CAB LA + RPV LA Q2M Arm

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.

    Time frame: Up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)

  14. Number of Participants With Non-serious Adverse Events (Non-SAEs >=5 Percent [%] Incidence) and Serious Adverse Events (SAEs) for DTG + RPV Arm

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.

    Time frame: Up to Month 12 [Maintenance Phase]

  15. Number of Participants With Severity of Adverse Events for CAB LA + RPV LA Q2M Arm

    Severity of adverse events were defined as per The Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS adverse events Grading Table). Severity grades for adverse events were Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 (all deaths related to an AE).

    Time frame: Up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)

  16. Number of Participants With Severity of Adverse Events for DTG + RPV Arm

    Severity of adverse events were defined as per The Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS adverse events Grading Table). Severity grades for adverse events were Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 (all deaths related to an AE).

    Time frame: Up to Month 12 [Maintenance Phase]

  17. Number of Participants With Maximum Post-Baseline Chemistry Toxicities for CAB LA + RPV LA Q2M Arm up to End of Maintenance Phase

    Clinical chemistry toxicities were graded as per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Blood samples were collected for the analysis of following clinical chemistry parameters: alanine aminotransferase (ALT), albumin, aspartate aminotransferase (AST), bilirubin, carbon dioxide (CO2), cholesterol, creatinine kinase, creatinine, direct bilirubin, glomerular filtration rate (GFR) from creatinine adjusted using chronic kidney disease epidemiology collaboration (CKD-EPI), GFR from creatinine adjusted for bovine serum albumin (BSA), glucose, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphate, sodium and triglycerides. Severity grades were: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).

    Time frame: Up to End of Maintenance Phase (up to Month 52)

  18. Number of Participants With Maximum Post-Baseline Chemistry Toxicities for DTG + RPV Arm up to Month 12 [Maintenance Phase]

    Clinical chemistry toxicities were graded as per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Blood samples were collected for the analysis of following clinical chemistry parameters: alanine aminotransferase (ALT), albumin, aspartate aminotransferase (AST), bilirubin, carbon dioxide (CO2), cholesterol, creatinine kinase, creatinine, direct bilirubin, glomerular filtration rate (GFR) from creatinine adjusted using chronic kidney disease epidemiology collaboration (CKD-EPI), GFR from creatinine adjusted for bovine serum albumin (BSA), glucose, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphate, sodium and triglycerides. Severity grades were: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).

    Time frame: Up to Month 12 [Maintenance Phase]

  19. Number of Participants With Maximum Post-Baseline Hematology Toxicities for CAB LA + RPV LA Q2M Arm up to End of Maintenance Phase

    The hematology toxicities were graded as per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Blood samples were collected for the analysis of the hematology parameter: platelets. Severity grades were: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).

    Time frame: Up to End of Maintenance Phase (up to Month 52)

  20. Number of Participants With Maximum Post-Baseline Hematology Toxicities for DTG + RPV Arm up to Month 12 [Maintenance Phase]

    The hematology toxicities were graded as per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Blood samples were collected for the analysis of the hematology parameter: platelets. Severity grades were: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).

    Time frame: Up to Month 12 [Maintenance Phase]

  21. Number of Participants Who Permanently Discontinued Treatment Due to Adverse Events for CAB LA + RPV LA Q2M Arm up to End of Maintenance Phase

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Number of participants with adverse events leading to permanent withdrawal has been presented.

    Time frame: Up to End of Maintenance Phase (up to Month 52)

  22. Number of Participants Who Permanently Discontinued Treatment Due to Adverse Events for DTG + RPV Arm up to Month 12 [Maintenance Phase]

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Number of participants with adverse events leading to permanent withdrawal has been presented.

    Time frame: Up to Month 12 [Maintenance Phase]

  23. Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Blood samples were collected for the analysis of clinical chemical parameters including ALT, ALP, AST and creatinine kinase. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)

  24. Change From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and Creatinine Kinase for DTG + RPV Arm up to Month 12 [Maintenance Phase]

    Blood samples were collected for the analysis of clinical chemical parameters including ALT, ALP, AST and creatinine kinase. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  25. Change From Baseline in Clinical Chemistry Parameter: Albumin for CAB LA + RPV LA Q2M Arm up to LTFU Phase

    Blood samples were collected for the analysis of clinical chemical parameter: albumin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value. SD=0.00 is defined as SD resulted below the detectable limit of the assay and approximate to 0.00.

    Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)

  26. Change From Baseline in Clinical Chemistry Parameter: Albumin for DTG+ RPV Arm up to Month 12 [Maintenance Phase]

    Blood samples were collected for the analysis of clinical chemistry parameter: albumin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  27. Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Blood samples were collected for the analysis of clinical chemistry parameters: bilirubin and creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)

  28. Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine for DTG+ RPV Arm up to Month 12 [Maintenance Phase]

    Blood samples were collected for the analysis of clinical chemistry parameters: bilirubin and creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  29. Change From Baseline in Clinical Chemistry Parameters: Carbon Dioxide, Chloride, Glucose, Phosphate, Potassium, Sodium and Urea for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Blood samples were collected for the analysis of clinical chemistry parameters: carbon dioxide, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value. SD=0.00(0) is defined as SD resulted below the detectable limit of the assay and approximate to 0.00(0).

    Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)

  30. Change From Baseline in Clinical Chemistry Parameters: Carbon Dioxide, Chloride, Glucose, Phosphate, Potassium, Sodium and Urea for DTG + RPV Arm up to Month 12 [Maintenance Phase]

    Blood samples were collected for the analysis of clinical chemistry parameters: carbon dioxide, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  31. Change From Baseline in Clinical Chemistry Parameters: Cholesterol, High Density Lipoprotein, Cholesterol Direct, Low Density Lipoprotein Cholesterol Calculation, and Cholesterol Direct, Triglycerides for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Blood samples were collected for the analysis of clinical chemistry parameters: cholesterol, direct high density lipoprotein cholesterol, LDL cholesterol calculation, direct low density lipoprotein cholesterol and triglycerides. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)

  32. Absolute Values of Clinical Chemistry Parameters: Cholesterol, Direct HDL Cholesterol, LDL Calculation, Direct LDL Cholesterol and Triglycerides for DTG + RPV Arm at Baseline

    Blood samples were collected for the analysis of clinical chemistry parameters: cholesterol, HDL cholesterol direct, LDL cholesterol calculation, LDL cholesterol direct and triglycerides.

    Time frame: At Baseline (Day 1)

  33. Change From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted Using CKD-EPI for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Blood samples were collected for the analysis of clinical chemistry parameter: GFR from creatinine adjusted using CKD-EPI. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)

  34. Change From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted Using CKD-EPI for DTG + RPV Arm up to Month 12 [Maintenance Phase]

    Blood samples were collected for the analysis of clinical chemistry parameter: GFR from creatinine adjusted using CKD-EPI. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  35. Change From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted BSA for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Blood samples were collected for the analysis of clinical chemistry parameter: GFR from creatinine adjusted for BSA. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)

  36. Change From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted BSA for DTG + RPV Arm up to Month 12 [Maintenance Phase]

    Blood samples were collected for the analysis of clinical chemistry parameter: GFR from creatinine adjusted for BSA. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  37. Change From Baseline in Clinical Chemistry Parameter: Lipase for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Blood samples were collected for the analysis of clinical chemistry parameter: lipase. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)

  38. Change From Baseline in Clinical Chemistry Parameter: Lipase for DTG + RPV Arm up to Month 12 [Maintenance Phase]

    Blood samples were collected for the analysis of clinical chemistry parameter: lipase. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  39. Change From Baseline in Clinical Chemistry Parameter: Total Cholesterol/ HDL Cholesterol Ratio for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Blood samples were collected for the analysis of clinical chemistry parameter: total cholesterol/ HDL cholesterol ratio. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)

  40. Change From Baseline in Clinical Chemistry Parameter: Total Cholesterol/ HDL Cholesterol Ratio for DTG + RPV Arm at Month 6 [Maintenance Phase]

    Blood samples were collected for the analysis of clinical chemistry parameter: total cholesterol/ HDL cholesterol ratio. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: At Month 6 (compared with Baseline [Day 1]) [Maintenance Phase]

  41. Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Blood samples were collected for the analysis of hematology parameters: basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)

  42. Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets for DTG + RPV Arm up to Month 12 [Maintenance Phase]

    Blood samples were collected for the analysis of hematology parameters: basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  43. Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Blood samples were collected for the analysis of hematology parameter: erythrocytes mean corpuscular volume. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)

  44. Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume for DTG + RPV Arm up to Month 12 [Maintenance Phase]

    Blood samples were collected for the analysis of hematology parameter: erythrocytes mean corpuscular volume. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  45. Change From Baseline in Hematology Parameter: Erythrocytes for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Blood samples were collected for the analysis of hematology parameter: erythrocytes. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value. SD=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.

    Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)

  46. Change From Baseline in Hematology Parameter: Erythrocytes for DTG + RPV Arm up to Month 12 [Maintenance Phase]

    Blood samples were collected for the analysis of hematology parameter: erythrocytes. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  47. Change From Baseline in Hematology Parameter: Hematocrit for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)

  48. Change From Baseline in Hematology Parameter: Hematocrit for DTG + RPV Arm up to Month 12 [Maintenance Phase]

    Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  49. Change From Baseline in Hematology Parameter: Hemoglobin for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

    Blood samples were collected for the analysis of hematology parameter: hemoglobin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)

  50. Change From Baseline in Hematology Parameter: Hemoglobin for DTG + RPV Arm up to Month 12 [Maintenance Phase]

    Blood samples were collected for the analysis of hematology parameter: hemoglobin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  51. Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio

    Urine samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio.

    Time frame: At Baseline (Day 1)

  52. Absolute Values of Urine Creatinine

    Urine samples were collected for the analysis of urine creatinine.

    Time frame: At Baseline (Day 1)

  53. Absolute Values of Urine Phosphate

    Urine samples were collected for the analysis of urine phosphate.

    Time frame: At Baseline (Day 1)

  54. Absolute Values of Urine Specific Gravity

    Urine samples were collected for the analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.

    Time frame: At Baseline (Day 1)

  55. Absolute Values of Urine Potential of Hydrogen (pH)

    Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0).

    Time frame: At Baseline (Day 1)

  56. Number of Participants With Treatment Emergent Genotypic Resistance

    Plasma samples were collected and analyzed for genotypic resistance from participants who met confirmed virologic withdrawal criteria.

    Time frame: Up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)

  57. Number of Participants With Treatment Emergent Phenotypic Resistance

    Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria.

    Time frame: Up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)

  58. Change From Baseline in HIV Dependent Quality of Life (HIVDQoL - Self-completion Questionnaire Designed to Measure QoL in People Living With HIV)

    HIVDQoL includes 2 overview items and 26 domain items. The 2 overview items: Item 1: 3(excellent) to -3(extremely bad); Higher score indicates better quality of life. Item 2: -3(very much better) to 1(worse); Lower score indicates better quality of life. The Weighted Impact Score (WIS) was calculated for the 26 domain items by multiplying impact score(IS) (-3\[maximum {max.} negative impact\] to +1\[max. positive impact\] by the corresponding importance score (3 \[very important\] to 0\[not all important\]). Average Weighted Impact (AWI) score was calculated by summing individual weighted IS and dividing by the number of domain items. The ranges of WIS and average IS were from -9(max. negative) to +3(max. positive);higher score indicates positive impact. Change from Baseline was defined as post-dose visit value minus Baseline value (latest pre-treatment assessment with a non-missing value). SD=0.00 is defined as SD resulted below the detectable limit of the assay and approximate to 0.00.

    Time frame: At Months 6 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  59. Change From Baseline in Total Treatment Satisfaction Score of HIV Treatment Satisfaction Status Questionnaire (HIVTSQs)

    HIVTSQs total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range of 0 to 66. Higher the score, greater improvement in satisfaction with treatment as compared to the past few weeks; lower score, greater the deterioration in satisfaction with treatment. A score of 0 represents no change. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

    Time frame: At Months 6 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  60. Change From Baseline in Individual Item Score of HIVTSQs

    HIVTSQs is a 12 item questionnaire. The individual item scores are rated as 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater treatment satisfaction as compared to the past few weeks. Change from Baseline is defined as post-dose value minus Baseline value. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. SD=0.00 is defined as SD resulted below the detectable limit of the assay and approximate to 0.00.

    Time frame: At Months 6 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]

  61. Change in Treatment Satisfaction Over Time Using the HIV Treatment Satisfaction Change Questionnaire (HIVTSQc)

    HIVTSQc (change version) total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range:-33 to 33. Higher scores represent greater improvement in treatment satisfaction compared to satisfaction with treatment received during the induction phase; lower scores represented deterioration in satisfaction with treatment. A score of 0 represents no change. A maximum of 5 items can be missing, the missing scores were imputed with the mean of the completed item scores. If 6 or more items are missing, then the overall treatment satisfaction scale score was not computed and remained missing.

    Time frame: At Month 12 (compared with Baseline [Day 1]) [Maintenance Phase]

Other outcomes

  1. Plasma Trough Concentration (Ctrough) for CAB LA

    Blood samples were collected at indicated time points for pharmacokinetic analysis of CAB LA. This was a conditional secondary endpoint for which results are not available because the trough concentrations for this product are well characterized and therefore, secondary population pharmacokinetic (Pop PK) analyses were not conducted.

    Time frame: Pre-dose (Day 1) and Month 12 [Maintenance Phase]

  2. Ctrough for RPV LA

    Blood samples were collected at indicated time points for pharmacokinetic analysis of RPV LA. This was a conditional secondary endpoint for which results are not available because the trough concentrations for this product are well characterized and therefore, secondary Pop PK analyses were not conducted.

    Time frame: Pre-dose (Day 1) and Month 12 [Maintenance Phase]

07

Results

Posted Jan 15, 2021

Participant flow

This was a multicenter, open-label, rollover study evaluating the efficacy, safety and tolerability of long acting (LA) cabotegravir (CAB) plus LA rilpivirine (RPV) administered every 2 months (Q2M) in human immunodeficiency virus-1 (HIV-1) adult participants who were virologically suppressed and participated in study LAI116482 (NCT01641809).

Maintenance Phase
Participant flow — Maintenance Phase
MilestoneCAB LA + RPV LA Q2MDTG + RPVLTFU: CAB LA+RPV LA Q2M Group
Started9070
Completed7670
Not completed1400
Withdrew: Lost to follow-up100
Withdrew: Adverse event100
Withdrew: Decision by subject or proxy700
Withdrew: Study site terminated by sponsor300
Withdrew: Subject reached protocol-defined stopping criteria100
Withdrew: Lack of efficacy100
Long-term Follow-up Phase (LTFU Phase)
Participant flow — Long-term Follow-up Phase (LTFU Phase)
MilestoneCAB LA + RPV LA Q2MDTG + RPVLTFU: CAB LA+RPV LA Q2M Group
Started006
Completed006
Not completed000

Outcome measures

PrimaryPercentage of Participants With HIV-ribonucleic Acid (RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Month 12 [Maintenance Phase]

Percentage of participants with HIV-1 RNA \>=50 c/mL as per FDA snapshot algorithm at Month 12 was assessed to demonstrate the antiviral activity of CAB LA+RPV LA Q2M and DTG + RPV regimen in HIV-1 infected antiretroviral therapy (ART) experienced participants. The HIV-1 RNA \>=50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window.

Time frame:
At Month 12 [Maintenance Phase]
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-ribonucleic Acid (RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Month 12 [Maintenance Phase]
Percentage of participantsCAB LA + RPV LA Q2MDTG + RPV
Percentage of Participants With HIV-ribonucleic Acid (RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Month 12 [Maintenance Phase]0 (0.0 to 4.0)0 (0.0 to 41.0)
SecondaryPercentage of Participants With HIV-RNA <50 c/mL as Per FDA Snapshot Algorithm at Month 12 [Maintenance Phase]

Percentage of participants with HIV-1 RNA \<50 c/mL as per FDA snapshot algorithm at Month 12 was assessed to demonstrate the antiviral activity of CAB LA+RPV LA Q2M and oral DTG + RPV regimen. The HIV-1 RNA \<50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window.

Time frame:
At Month 12 [Maintenance Phase]
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-RNA <50 c/mL as Per FDA Snapshot Algorithm at Month 12 [Maintenance Phase]
Percentage of participantsCAB LA + RPV LA Q2MDTG + RPV
Percentage of Participants With HIV-RNA <50 c/mL as Per FDA Snapshot Algorithm at Month 12 [Maintenance Phase]98 (95 to 100)100 (59 to 100)
SecondaryNumber of Participants With Protocol-defined Confirmed Virologic Failure up to End of Maintenance Phase

Confirmed virologic failure was defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 c/mL after prior suppression to \<200 c/mL.

Time frame:
Up to End of Maintenance Phase (up to Month 52 for CAB LA+RPV LA Q2M group, up to Month 12 for DTG+RPV group)
Reported as:
Count of participants · Participants
Number of Participants With Protocol-defined Confirmed Virologic Failure up to End of Maintenance Phase
ParticipantsCAB LA + RPV LA Q2MDTG + RPV
Number of Participants With Protocol-defined Confirmed Virologic Failure up to End of Maintenance Phase10
SecondaryPercentage of Participants With HIV-RNA >=50 c/mL as Per FDA Snapshot Algorithm Over Time for CAB LA + RPV LA Q2M Arm up to Month 12 [Maintenance Phase]

Percentage of participants with HIV-1 RNA \>=50 c/mL as per FDA snapshot algorithm over time was assessed to demonstrate the antiviral activity of CAB LA+RPV LA Q2M regimen in HIV-1 infected ART experienced participants. The HIV-1 RNA \>=50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
At Baseline (Day 1) and at Months 2, 4, 6, 8, 10 and 12 [Maintenance Phase]
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-RNA >=50 c/mL as Per FDA Snapshot Algorithm Over Time for CAB LA + RPV LA Q2M Arm up to Month 12 [Maintenance Phase]
Percentage of participantsCAB LA + RPV LA Q2M
Baseline (Day 1)0 (0.0 to 4.0)
Month 20 (0.0 to 4.0)
Month 41 (0.0 to 3.3)
Month 60 (0.0 to 4.0)
Month 80 (0.0 to 4.0)
Month 100 (0.0 to 4.0)
Month 120 (0.0 to 4.0)
SecondaryPercentage of Participants With HIV-RNA >=50 c/mL as Per FDA Snapshot Algorithm Over Time for DTG + RPV up to Month 12 [Maintenance Phase]

Percentage of participants with HIV-1 RNA \>=50 c/mL as per FDA snapshot algorithm over time was assessed to demonstrate the antiviral activity of DTG + RPV regimen in HIV-1 infected ART experienced participants. The HIV-1 RNA \>=50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
At Baseline (Day 1) and at Months 3, 6, 9 and 12 [Maintenance Phase]
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-RNA >=50 c/mL as Per FDA Snapshot Algorithm Over Time for DTG + RPV up to Month 12 [Maintenance Phase]
Percentage of participantsDTG + RPV
Baseline (Day 1)0.0 (0.0 to 41.0)
Month 30.0 (0.0 to 41.0)
Month 60.0 (0.0 to 41.0)
Month 90.0 (0.0 to 41.0)
Month 120.0 (0.0 to 41.0)
SecondaryAbsolute Values for HIV-1 RNA of CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Plasma samples were collected for quantitative analysis of HIV-1 RNA. Logarithm to base 10 (log10) values for plasma HIV-1 RNA have been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Standard Deviation (SD)=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.

Time frame:
From Baseline (Day 1) up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · Log 10 copies per milliliter
Absolute Values for HIV-1 RNA of CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Log 10 copies per milliliterCAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Baseline (Day 1)1.591 ± 0.0085—
Month 21.590 ± 0.0000—
Month 41.594 ± 0.0305—
Month 61.590 ± 0.0042—
Month 81.590 ± 0.0000—
Month 101.594 ± 0.0384—
Month 121.590 ± 0.0000—
Month 141.593 ± 0.0216—
Month 161.598 ± 0.0555—
Month 181.592 ± 0.0217—
Month 201.592 ± 0.0153—
Month 221.590 ± 0.0000—
Month 241.602 ± 0.0882—
Month 261.611 ± 0.1246—
Month 281.594 ± 0.0334—
Month 301.590 ± 0.0000—
Month 321.590 ± 0.0000—
Month 341.590 ± 0.0000—
Month 361.590 ± 0.0000—
Month 381.590 ± 0.0000—
Month 401.590 ± 0.0000—
Month 421.590 ± 0.0000—
Month 441.591 ± 0.0104—
Month 461.590 ± 0.0000—
Month 481.590 ± 0.0025—
Month 501.590 ± 0.0000—
Month 521.590 ± 0.0000—
LTFU Month 1—1.852 ± 0.4338
LTFU Month 3—1.590 ± 0.0000
LTFU Month 6—1.590 ± 0.0000
LTFU Month 9—2.027 ± 1.0696
LTFU Month 12—1.616 ± 0.0581
SecondaryAbsolute Values for HIV-1 RNA of DTG + RPV Arm up to Month 12 [Maintenance Phase]

Plasma samples were collected for quantitative analysis of HIV-1 RNA. Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. SD=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.

Time frame:
At Baseline (Day 1) and at Months 3, 6, 9 and 12 [Maintenance Phase]
Reported as:
Mean · Log 10 copies per milliliter
Absolute Values for HIV-1 RNA of DTG + RPV Arm up to Month 12 [Maintenance Phase]
Log 10 copies per milliliterDTG + RPV
Baseline (Day 1)1.590 ± 0.0000
Month 31.590 ± 0.0000
Month 61.590 ± 0.0000
Month 91.590 ± 0.0000
Month 121.590 ± 0.0000
SecondaryChange From Baseline in HIV-1 RNA for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Plasma samples were collected for quantitative analysis of HIV-1 RNA. Log 10 values for plasma HIV-1 RNA has been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline value is defined as post-dose value minus baseline value. SD=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.

Time frame:
Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · Log 10 copies per milliliter
Change From Baseline in HIV-1 RNA for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Log 10 copies per milliliterCAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Month 2-0.001 ± 0.0085—
Month 40.003 ± 0.0299—
Month 6-0.000 ± 0.0096—
Month 8-0.001 ± 0.0085—
Month 100.003 ± 0.0396—
Month 12-0.001 ± 0.0086—
Month 140.002 ± 0.0234—
Month 160.007 ± 0.0529—
Month 180.001 ± 0.0235—
Month 200.001 ± 0.0177—
Month 22-0.001 ± 0.0087—
Month 240.011 ± 0.0888—
Month 260.020 ± 0.1251—
Month 280.003 ± 0.0346—
Month 30-0.001 ± 0.0088—
Month 32-0.001 ± 0.0087—
Month 34-0.001 ± 0.0087—
Month 36-0.001 ± 0.0088—
Month 380.000 ± 0.0000—
Month 40-0.001 ± 0.0091—
Month 42-0.001 ± 0.0091—
Month 440.000 ± 0.0140—
Month 46-0.001 ± 0.0096—
Month 48-0.001 ± 0.0102—
Month 500.000 ± 0.0000—
Month 520.000 ± 0.0000—
LTFU Month 1—0.262 ± 0.4338
LTFU Month 3—0.000 ± 0.0000
LTFU Month 6—0.000 ± 0.0000
LTFU Month 9—0.437 ± 1.0696
LTFU Month 12—0.026 ± 0.0581
SecondaryChange From Baseline in HIV-1 RNA for DTG + RPV Arm up to Month 12 [Maintenance Phase]

Plasma samples were collected for quantitative analysis of HIV-1 RNA. Log 10 values for plasma HIV-1 RNA has been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline value is defined as post-dose value minus baseline value. SD=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.

Time frame:
At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · Log 10 copies per milliliter
Change From Baseline in HIV-1 RNA for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Log 10 copies per milliliterDTG + RPV
Month 30.000 ± 0.0000
Month 60.000 ± 0.0000
Month 90.000 ± 0.0000
Month 120.000 ± 0.0000
SecondaryAbsolute Values for Cluster of Differentiation 4 Plus (CD4+) for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunologic activity of CAB LA+RPV LA Q2M. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
From Baseline (Day 1) up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · Cells per cubic millimeter
Absolute Values for Cluster of Differentiation 4 Plus (CD4+) for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Cells per cubic millimeterCAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Baseline (Day 1)873.0 ± 233.37—
Month 2868.1 ± 261.49—
Month 4879.8 ± 280.88—
Month 61046.8 ± 435.74—
Month 8857 ± 277.46—
Month 12859.2 ± 283.23—
Month 16917.5 ± 295.27—
Month 20912.8 ± 262.40—
Month 24910.3 ± 286.21—
Month 26905.9 ± 274.22—
Month 28867.3 ± 266.36—
Month 30931.1 ± 220.94—
Month 32853.7 ± 280.49—
Month 34967.3 ± 300.72—
Month 36865.4 ± 225.93—
Month 40925.7 ± 271.70—
Month 421220.8 ± 536.73—
Month 44905.7 ± 292.61—
Month 461011.0 ± 292.74—
Month 48818.5 ± 291.82—
Month 50755.0 ± 182.43—
Month 52716.3 ± 143.21—
LTFU Month 1—837.2 ± 224.49
LTFU Month 3—717.8 ± 188.88
LTFU Month 6—766.5 ± 184.84
LTFU Month 9—775.0 ± 293.45
LTFU Month 12—954.8 ± 259.47
SecondaryAbsolute Values for CD4+ for DTG + RPV Arm up to Month 12 [Maintenance Phase]

Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunologic activity of DTG + RPV arm. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
At Baseline (Day 1) and at Months 3, 6, 9 and 12 [Maintenance Phase]
Reported as:
Mean · Cells per cubic millimeter
Absolute Values for CD4+ for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Cells per cubic millimeterDTG + RPV
Baseline (Day 1)804.3 ± 167.73
Month 3780.3 ± 145.22
Month 6728.9 ± 147.06
Month 9777.0 ± 251.37
Month 12790.4 ± 141.80
SecondaryChange From Baseline Values for CD4+ for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunologic activity of CAB LA+RPV LA Q2M. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline value is defined as post-dose value minus baseline value.

Time frame:
Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · Cells per cubic millimeter
Change From Baseline Values for CD4+ for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Cells per cubic millimeterCAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Month 2-4.9 ± 196.47—
Month 45.3 ± 221.68—
Month 6100.2 ± 343.66—
Month 8-20.7 ± 218.39—
Month 12-19.4 ± 189.19—
Month 1645.6 ± 227.11—
Month 2043.8 ± 193.72—
Month 2441.6 ± 224.99—
Month 264.2 ± 160.08—
Month 28-6.2 ± 196.62—
Month 3018.1 ± 192.09—
Month 32-13.5 ± 215.60—
Month 3415.8 ± 239.28—
Month 360.0 ± 195.92—
Month 4067.1 ± 205.26—
Month 42390.8 ± 406.79—
Month 4431.6 ± 244.33—
Month 46-98.5 ± 424.97—
Month 48-44.2 ± 236.71—
Month 50-451.0 ± 485.08—
Month 52-23.0 ± 78.28—
LTFU Month 1—-88.8 ± 156.64
LTFU Month 3—-97.8 ± 188.52
LTFU Month 6—-111.8 ± 236.26
LTFU Month 9—-103.3 ± 87.22
LTFU Month 12—28.8 ± 209.33
SecondaryChange From Baseline Values for CD4+ for DTG + RPV Arm up to Month 12 [Maintenance Phase]

Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunologic activity of DTG + RPV arm. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline value is defined as post-dose value minus baseline value.

Time frame:
At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · Cells per cubic millimeter
Change From Baseline Values for CD4+ for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Cells per cubic millimeterDTG + RPV
Month 3-24.0 ± 118.40
Month 6-75.4 ± 123.71
Month 9-27.3 ± 150.96
Month 12-13.9 ± 145.76
SecondaryNumber of Participants With Non-serious Adverse Events (Non-SAEs >=5 Percent [%] Incidence) and Serious Adverse Events (SAEs) for CAB LA + RPV LA Q2M Arm

An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.

Time frame:
Up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Non-serious Adverse Events (Non-SAEs >=5 Percent [%] Incidence) and Serious Adverse Events (SAEs) for CAB LA + RPV LA Q2M Arm
ParticipantsCAB LA + RPV LA Q2M
Non-SAE (>=5%)86
SAE10
SecondaryNumber of Participants With Non-serious Adverse Events (Non-SAEs >=5 Percent [%] Incidence) and Serious Adverse Events (SAEs) for DTG + RPV Arm

An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.

Time frame:
Up to Month 12 [Maintenance Phase]
Reported as:
Count of participants · Participants
Number of Participants With Non-serious Adverse Events (Non-SAEs >=5 Percent [%] Incidence) and Serious Adverse Events (SAEs) for DTG + RPV Arm
ParticipantsDTG + RPV
Non-SAE (>=5%)3
SAE0
SecondaryNumber of Participants With Severity of Adverse Events for CAB LA + RPV LA Q2M Arm

Severity of adverse events were defined as per The Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS adverse events Grading Table). Severity grades for adverse events were Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 (all deaths related to an AE).

Time frame:
Up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Severity of Adverse Events for CAB LA + RPV LA Q2M Arm
ParticipantsCAB LA + RPV LA Q2M
Grade 122
Grade 253
Grade 310
Grade 44
Grade 50
SecondaryNumber of Participants With Severity of Adverse Events for DTG + RPV Arm

Severity of adverse events were defined as per The Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS adverse events Grading Table). Severity grades for adverse events were Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 (all deaths related to an AE).

Time frame:
Up to Month 12 [Maintenance Phase]
Reported as:
Count of participants · Participants
Number of Participants With Severity of Adverse Events for DTG + RPV Arm
ParticipantsDTG + RPV
Grade 10
Grade 23
Grade 30
Grade 40
Grade 50
SecondaryNumber of Participants With Maximum Post-Baseline Chemistry Toxicities for CAB LA + RPV LA Q2M Arm up to End of Maintenance Phase

Clinical chemistry toxicities were graded as per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Blood samples were collected for the analysis of following clinical chemistry parameters: alanine aminotransferase (ALT), albumin, aspartate aminotransferase (AST), bilirubin, carbon dioxide (CO2), cholesterol, creatinine kinase, creatinine, direct bilirubin, glomerular filtration rate (GFR) from creatinine adjusted using chronic kidney disease epidemiology collaboration (CKD-EPI), GFR from creatinine adjusted for bovine serum albumin (BSA), glucose, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphate, sodium and triglycerides. Severity grades were: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).

Time frame:
Up to End of Maintenance Phase (up to Month 52)
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline Chemistry Toxicities for CAB LA + RPV LA Q2M Arm up to End of Maintenance Phase
ParticipantsCAB LA + RPV LA Q2M
ALT, Grade 115
ALT, Grade 23
ALT, Grade 33
ALT, Grade 40
AST, Grade 112
AST, Grade 26
AST, Grade 30
AST, Grade 40
Bilirubin, Grade 14
Bilirubin, Grade 21
Bilirubin, Grade 30
Bilirubin, Grade 40
CO2, Grade 113
CO2, Grade 20
CO2, Grade 30
CO2, Grade 40
Cholesterol, Grade 18
Cholesterol, Grade 25
Cholesterol, Grade 30
Cholesterol, Grade 40
Creatine kinase, Grade 18
Creatine kinase, Grade 27
Creatine kinase, Grade 36
Creatine kinase, Grade 42
Creatinine, Grade 13
Creatinine, Grade 20
Creatinine, Grade 30
Creatinine, Grade 40
Direct bilirubin, Grade 10
Direct bilirubin, Grade 20
Direct bilirubin, Grade 31
Direct bilirubin, Grade 40
GFR from creatinine adjusted using CKD-EPI, Grade 10
GFR from creatinine adjusted using CKD-EPI, Grade 223
GFR from creatinine adjusted using CKD-EPI, Grade 33
GFR from creatinine adjusted using CKD-EPI, Grade 40
GFR from creatinine adjusted for BSA, Grade 10
GFR from creatinine adjusted for BSA, Grade 223
GFR from creatinine adjusted for BSA, Grade 33
GFR from creatinine adjusted for BSA, Grade 40
Glucose, Grade 121
Glucose, Grade 220
Glucose, Grade 30
Glucose, Grade 40
LDL cholesterol calculation, Grade 17
LDL cholesterol calculation, Grade 24
LDL cholesterol calculation, Grade 31
LDL cholesterol calculation, Grade 40
Lipase, Grade 110
Lipase, Grade 215
Lipase, Grade 33
Lipase, Grade 44
Phosphate, Grade 114
Phosphate, Grade 22
Phosphate, Grade 30
Phosphate, Grade 40
Sodium, Grade 19
Sodium, Grade 21
Sodium, Grade 30
Sodium, Grade 40
Triglycerides, Grade 111
Triglycerides, Grade 28
Triglycerides, Grade 32
Triglycerides, Grade 41
SecondaryNumber of Participants With Maximum Post-Baseline Chemistry Toxicities for DTG + RPV Arm up to Month 12 [Maintenance Phase]

Clinical chemistry toxicities were graded as per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Blood samples were collected for the analysis of following clinical chemistry parameters: alanine aminotransferase (ALT), albumin, aspartate aminotransferase (AST), bilirubin, carbon dioxide (CO2), cholesterol, creatinine kinase, creatinine, direct bilirubin, glomerular filtration rate (GFR) from creatinine adjusted using chronic kidney disease epidemiology collaboration (CKD-EPI), GFR from creatinine adjusted for bovine serum albumin (BSA), glucose, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphate, sodium and triglycerides. Severity grades were: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).

Time frame:
Up to Month 12 [Maintenance Phase]
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline Chemistry Toxicities for DTG + RPV Arm up to Month 12 [Maintenance Phase]
ParticipantsDTG + RPV
ALT, Grade 11
ALT, Grade 20
ALT, Grade 30
ALT, Grade 40
AST, Grade 10
AST, Grade 20
AST, Grade 30
AST, Grade 40
Bilirubin, Grade 10
Bilirubin, Grade 20
Bilirubin, Grade 30
Bilirubin, Grade 40
CO2, Grade 11
CO2, Grade 20
CO2, Grade 30
CO2, Grade 40
Cholesterol, Grade 10
Cholesterol, Grade 20
Cholesterol, Grade 30
Cholesterol, Grade 40
Creatine kinase, Grade 10
Creatine kinase, Grade 20
Creatine kinase, Grade 30
Creatine kinase, Grade 40
Creatinine, Grade 10
Creatinine, Grade 20
Creatinine, Grade 30
Creatinine, Grade 40
Direct bilirubin, Grade 10
Direct bilirubin, Grade 20
Direct bilirubin, Grade 30
Direct bilirubin, Grade 40
GFR from creatinine adjusted using CKD-EPI, Grade 10
GFR from creatinine adjusted using CKD-EPI, Grade 25
GFR from creatinine adjusted using CKD-EPI, Grade 31
GFR from creatinine adjusted using CKD-EPI, Grade 40
GFR from creatinine adjusted for BSA, Grade 10
GFR from creatinine adjusted for BSA, Grade 25
GFR from creatinine adjusted for BSA, Grade 31
GFR from creatinine adjusted for BSA, Grade 40
Glucose, Grade 11
Glucose, Grade 20
Glucose, Grade 30
Glucose, Grade 40
LDL cholesterol calculation, Grade 10
LDL cholesterol calculation, Grade 20
LDL cholesterol calculation, Grade 30
LDL cholesterol calculation, Grade 40
Lipase, Grade 10
Lipase, Grade 22
Lipase, Grade 30
Lipase, Grade 40
Phosphate, Grade 10
Phosphate, Grade 20
Phosphate, Grade 30
Phosphate, Grade 40
Sodium, Grade 10
Sodium, Grade 20
Sodium, Grade 30
Sodium, Grade 40
Triglycerides, Grade 10
Triglycerides, Grade 20
Triglycerides, Grade 30
Triglycerides, Grade 40
SecondaryNumber of Participants With Maximum Post-Baseline Hematology Toxicities for CAB LA + RPV LA Q2M Arm up to End of Maintenance Phase

The hematology toxicities were graded as per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Blood samples were collected for the analysis of the hematology parameter: platelets. Severity grades were: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).

Time frame:
Up to End of Maintenance Phase (up to Month 52)
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline Hematology Toxicities for CAB LA + RPV LA Q2M Arm up to End of Maintenance Phase
ParticipantsCAB LA + RPV LA Q2M
Platelets, Grade 12
Platelets, Grade 20
Platelets, Grade 30
Platelets, Grade 40
SecondaryNumber of Participants With Maximum Post-Baseline Hematology Toxicities for DTG + RPV Arm up to Month 12 [Maintenance Phase]

The hematology toxicities were graded as per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Blood samples were collected for the analysis of the hematology parameter: platelets. Severity grades were: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).

Time frame:
Up to Month 12 [Maintenance Phase]
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline Hematology Toxicities for DTG + RPV Arm up to Month 12 [Maintenance Phase]
ParticipantsDTG + RPV
Platelets, Grade 10
Platelets, Grade 20
Platelets, Grade 30
Platelets, Grade 40
SecondaryNumber of Participants Who Permanently Discontinued Treatment Due to Adverse Events for CAB LA + RPV LA Q2M Arm up to End of Maintenance Phase

An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Number of participants with adverse events leading to permanent withdrawal has been presented.

Time frame:
Up to End of Maintenance Phase (up to Month 52)
Reported as:
Count of participants · Participants
Number of Participants Who Permanently Discontinued Treatment Due to Adverse Events for CAB LA + RPV LA Q2M Arm up to End of Maintenance Phase
ParticipantsCAB LA + RPV LA Q2M
Number of Participants Who Permanently Discontinued Treatment Due to Adverse Events for CAB LA + RPV LA Q2M Arm up to End of Maintenance Phase1
SecondaryNumber of Participants Who Permanently Discontinued Treatment Due to Adverse Events for DTG + RPV Arm up to Month 12 [Maintenance Phase]

An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Number of participants with adverse events leading to permanent withdrawal has been presented.

Time frame:
Up to Month 12 [Maintenance Phase]
Reported as:
Count of participants · Participants
Number of Participants Who Permanently Discontinued Treatment Due to Adverse Events for DTG + RPV Arm up to Month 12 [Maintenance Phase]
ParticipantsDTG + RPV
Number of Participants Who Permanently Discontinued Treatment Due to Adverse Events for DTG + RPV Arm up to Month 12 [Maintenance Phase]0
SecondaryChange From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Blood samples were collected for the analysis of clinical chemical parameters including ALT, ALP, AST and creatinine kinase. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · International units per liter
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
International units per literCAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
ALT, Month 2-1.1 ± 16.99—
ALT, Month 4-1.0 ± 26.15—
ALT, Month 80.0 ± 29.86—
ALT, Month 124.0 ± 44.62—
ALT, Month 14-7.5 ± 61.52—
ALT, Month 16-2.5 ± 24.07—
ALT, Month 20-3.4 ± 18.61—
ALT, Month 24-3.0 ± 17.53—
ALT, Month 26-21.7 ± 49.26—
ALT, Month 281.0 ± 31.18—
ALT, Month 3011.2 ± 49.09—
ALT, Month 32-0.9 ± 18.02—
ALT, Month 34-7.0 ± 30.17—
ALT, Month 360.2 ± 18.90—
ALT, Month 382.5 ± 4.95—
ALT, Month 40-1.7 ± 19.97—
ALT, Month 42-1.5 ± 6.36—
ALT, Month 44-0.5 ± 14.51—
ALT, Month 460.5 ± 3.79—
ALT, Month 48-2.6 ± 11.38—
ALT, Month 50-4.5 ± 7.78—
ALT, Month 52-3.5 ± 13.62—
ALT, LTFU Month 1—-5.0 ± 7.07
ALT, LTFU Month 3—2.8 ± 29.93
ALT, LTFU Month 6—-7.7 ± 48.87
ALT, LTFU Month 9—-6.0 ± 15.17
ALT, LTFU Month 12—0.2 ± 54.36
ALP, Month 20.2 ± 8.29—
ALP, Month 40.2 ± 14.20—
ALP, Month 82.0 ± 11.58—
ALP, Month 122.1 ± 12.39—
ALP, Month 14-15.5 ± 33.23—
ALP, Month 161.7 ± 10.83—
ALP, Month 205.5 ± 11.50—
ALP, Month 242.3 ± 12.64—
ALP, Month 26-2.2 ± 23.09—
ALP, Month 281.0 ± 12.89—
ALP, Month 302.3 ± 19.06—
ALP, Month 322.4 ± 11.79—
ALP, Month 340.4 ± 10.26—
ALP, Month 363.3 ± 9.81—
ALP, Month 38-10.0 ± 14.14—
ALP, Month 405.7 ± 14.32—
ALP, Month 427.0 ± 2.83—
ALP, Month 445.3 ± 16.34—
ALP, Month 461.8 ± 7.89—
ALP, Month 483.3 ± 12.21—
ALP, Month 5010.5 ± 2.12—
ALP, Month 52-2.5 ± 7.12—
ALP, LTFU Month 1—-3.6 ± 19.24
ALP, LTFU Month 3—-10.3 ± 23.91
ALP, LTFU Month 6—-5.0 ± 24.71
ALP, LTFU Month 9—-5.7 ± 18.28
ALP, LTFU Month 12—0.0 ± 26.31
AST, Month 2-5.6 ± 47.9—
AST, Month 4-5.0 ± 50.5—
AST, Month 8-5.3 ± 49.56—
AST, Month 12-2.7 ± 54.93—
AST, Month 140.0 ± 16.97—
AST, Month 16-5.1 ± 51.27—
AST, Month 20-7.5 ± 49.83—
AST, Month 24-7.2 ± 50.49—
AST, Month 26-11.5 ± 15.35—
AST, Month 28-7.3 ± 57.53—
AST, Month 303.3 ± 29.38—
AST, Month 32-6.7 ± 51.96—
AST, Month 34-6.4 ± 16.56—
AST, Month 36-5.0 ± 54.45—
AST, Month 38-2.0 ± 7.07—
AST, Month 40-8.4 ± 52.46—
AST, Month 42-0.5 ± 3.54—
AST, Month 44-2.0 ± 9.01—
AST, Month 46-4.3 ± 3.59—
AST, Month 48-3.0 ± 8.02—
AST, Month 50-4.5 ± 3.54—
AST, Month 52-6.0 ± 7.90—
AST, LTFU Month 1—3.6 ± 18.68
AST, LTFU Month 3—8.5 ± 4.51
AST, LTFU Month 6—1.5 ± 12.82
AST, LTFU Month 9—1.5 ± 6.86
AST, LTFU Month 12—14.6 ± 41.38
Creatine kinase, Month 2-255.2 ± 2327.32—
Creatine kinase, Month 4-204.0 ± 2483.41—
Creatine kinase, Month 8-237.0 ± 2362.99—
Creatine kinase, Month 12-252.0 ± 2429.86—
Creatine kinase, Month 14120.0 ± NA—
Creatine kinase, Month 16-245.1 ± 2421.43—
Creatine kinase, Month 20-292.8 ± 2390.38—
Creatine kinase, Month 24-290.0 ± 2435.94—
Creatine kinase, Month 26-44.0 ± 115.53—
Creatine kinase, Month 28-393.7 ± 2738.54—
Creatine kinase, Month 30-33.2 ± 238.35—
Creatine kinase, Month 32-276.7 ± 2518.73—
Creatine kinase, Month 34-17.0 ± 173.27—
Creatine kinase, Month 36-318.6 ± 2488.91—
Creatine kinase, Month 38-21.0 ± 32.53—
Creatine kinase, Month 40-341.7 ± 2552.60—
Creatine kinase, Month 4230.5 ± 31.82—
Creatine kinase, Month 44-15.9 ± 463.41—
Creatine kinase, Month 466.0 ± 50.28—
Creatine kinase, Month 481.0 ± 140.26—
Creatine kinase, Month 50-136.5 ± 178.90—
Creatine kinase, Month 52-67.7 ± 84.29—
Creatine kinase, LTFU Month 1—-18.0 ± 21.76
Creatine kinase, LTFU Month 3—81.3 ± 245.69
Creatine kinase, LTFU Month 6—50.8 ± 157.89
Creatine kinase, LTFU Month 9—-8.8 ± 88.04
Creatine kinase, LTFU Month 12—844.2 ± 1731.52
SecondaryChange From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and Creatinine Kinase for DTG + RPV Arm up to Month 12 [Maintenance Phase]

Blood samples were collected for the analysis of clinical chemical parameters including ALT, ALP, AST and creatinine kinase. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · International units per liter
Change From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and Creatinine Kinase for DTG + RPV Arm up to Month 12 [Maintenance Phase]
International units per literDTG + RPV
ALT, Month 3-0.7 ± 22.37
ALT, Month 6-4.3 ± 19.99
ALT, Month 91.7 ± 8.16
ALT, Month 12-0.3 ± 32.32
ALP, Month 31.4 ± 10.11
ALP, Month 61.6 ± 8.04
ALP, Month 9-1.1 ± 11.74
ALP, Month 1210.0 ± 33.16
AST, Month 3-0.6 ± 10.61
AST, Month 6-3.3 ± 7.30
AST, Month 9-1.4 ± 6.68
AST, Month 12-0.6 ± 14.68
Creatine kinase, Month 3-66.6 ± 287.66
Creatine kinase, Month 6-107.9 ± 112.18
Creatine kinase, Month 9-90.6 ± 163.40
Creatine kinase, Month 12-134.0 ± 149.59
SecondaryChange From Baseline in Clinical Chemistry Parameter: Albumin for CAB LA + RPV LA Q2M Arm up to LTFU Phase

Blood samples were collected for the analysis of clinical chemical parameter: albumin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value. SD=0.00 is defined as SD resulted below the detectable limit of the assay and approximate to 0.00.

Time frame:
Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · Grams per liter
Change From Baseline in Clinical Chemistry Parameter: Albumin for CAB LA + RPV LA Q2M Arm up to LTFU Phase
Grams per literCAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Month 2-0.8 ± 2.31—
Month 4-0.9 ± 2.46—
Month 8-0.8 ± 2.63—
Month 12-0.9 ± 2.67—
Month 142.0 ± NA—
Month 16-0.7 ± 2.81—
Month 20-0.3 ± 2.47—
Month 24-0.8 ± 2.98—
Month 260.8 ± 2.56—
Month 28-1.1 ± 2.68—
Month 30-0.3 ± 1.51—
Month 32-1.2 ± 2.69—
Month 34-0.8 ± 2.68—
Month 36-1.1 ± 2.80—
Month 38-1.0 ± 1.41—
Month 40-0.9 ± 3.00—
Month 42-3.0 ± 0.00—
Month 44-0.9 ± 2.50—
Month 46-3.3 ± 3.50—
Month 48-1.4 ± 2.56—
Month 50-2.5 ± 2.12—
Month 52-1.0 ± 2.00—
LTFU Month 1—-3.4 ± 2.88
LTFU Month 3—-1.5 ± 1.29
LTFU Month 6—-3.0 ± 3.22
LTFU Month 9—-2.8 ± 3.06
LTFU Month 12—-3.2 ± 2.05
SecondaryChange From Baseline in Clinical Chemistry Parameter: Albumin for DTG+ RPV Arm up to Month 12 [Maintenance Phase]

Blood samples were collected for the analysis of clinical chemistry parameter: albumin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · Grams per liter
Change From Baseline in Clinical Chemistry Parameter: Albumin for DTG+ RPV Arm up to Month 12 [Maintenance Phase]
Grams per literDTG + RPV
Month 3-1.6 ± 3.87
Month 6-1.4 ± 2.30
Month 9-1.3 ± 2.63
Month 12-2.6 ± 2.37
SecondaryChange From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Blood samples were collected for the analysis of clinical chemistry parameters: bilirubin and creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · Micromoles per liter
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Micromoles per literCAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Bilirubin, Month 2-1.0 ± 4.33—
Bilirubin, Month 4-1.0 ± 5.14—
Bilirubin, Month 8-1.0 ± 4.83—
Bilirubin, Month 12-0.5 ± 4.35—
Bilirubin, Month 142.0 ± 8.49—
Bilirubin, Month 16-1.0 ± 4.99—
Bilirubin, Month 20-1.4 ± 3.76—
Bilirubin, Month 24-0.8 ± 5.16—
Bilirubin, Month 260.0 ± 4.56—
Bilirubin, Month 28-0.9 ± 3.36—
Bilirubin, Month 302.0 ± 3.58—
Bilirubin, Month 32-1.0 ± 5.40—
Bilirubin, Month 340.0 ± 7.07—
Bilirubin, Month 36-0.4 ± 4.02—
Bilirubin, Month 38-2.0 ± 2.83—
Bilirubin, Month 40-1.6 ± 4.87—
Bilirubin, Month 42-1.0 ± 4.24—
Bilirubin, Month 44-0.9 ± 4.36—
Bilirubin, Month 46-3.5 ± 2.52—
Bilirubin, Month 48-1.7 ± 3.92—
Bilirubin, Month 501.0 ± 1.41—
Bilirubin, Month 52-1.3 ± 4.68—
Bilirubin, LTFU Month 1—-3.2 ± 5.76
Bilirubin, LTFU Month 3—1.5 ± 7.72
Bilirubin, LTFU Month 6—1.3 ± 9.27
Bilirubin, LTFU Month 9—1.0 ± 9.10
Bilirubin, LTFU Month 12—-0.8 ± 6.10
Creatinine, Month 2-1.84 ± 7.121—
Creatinine, Month 4-1.70 ± 9.393—
Creatinine, Month 8-0.98 ± 7.977—
Creatinine, Month 10-1.14 ± 9.204—
Creatinine, Month 14-1.80 ± NA—
Creatinine, Month 161.15 ± 9.508—
Creatinine, Month 20-0.50 ± 9.569—
Creatinine, Month 243.57 ± 10.039—
Creatinine, Month 261.03 ± 9.423—
Creatinine, Month 284.64 ± 10.159—
Creatinine, Month 309.87 ± 8.190—
Creatinine, Month 321.07 ± 9.648—
Creatinine, Month 341.06 ± 8.331—
Creatinine, Month 360.76 ± 9.661—
Creatinine, Month 380.27 ± 4.007—
Creatinine, Month 40-2.71 ± 8.065—
Creatinine, Month 424.73 ± 7.524—
Creatinine, Month 440.11 ± 11.223—
Creatinine, Month 468.63 ± 13.822—
Creatinine, Month 480.01 ± 9.828—
Creatinine, Month 50-3.50 ± 4.950—
Creatinine, Month 52-2.50 ± 16.393—
Creatinine, LTFU Month 1—3.00 ± 12.761
Creatinine, LTFU Month 3—13.48 ± 9.469
Creatinine, LTFU Month 6—8.42 ± 12.726
Creatinine, LTFU Month 9—6.65 ± 7.731
Creatinine, LTFU Month 12—9.74 ± 7.416
SecondaryChange From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine for DTG+ RPV Arm up to Month 12 [Maintenance Phase]

Blood samples were collected for the analysis of clinical chemistry parameters: bilirubin and creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · Micromoles per liter
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine for DTG+ RPV Arm up to Month 12 [Maintenance Phase]
Micromoles per literDTG + RPV
Bilirubin, Month 3-1.7 ± 4.23
Bilirubin, Month 6-1.4 ± 3.21
Bilirubin, Month 9-0.9 ± 2.54
Bilirubin, Month 12-1.4 ± 3.78
Creatinine, Month 311.89 ± 8.89
Creatinine, Month 68.36 ± 4.419
Creatinine, Month 916.56 ± 10.131
Creatinine, Month 127.47 ± 7.328
SecondaryChange From Baseline in Clinical Chemistry Parameters: Carbon Dioxide, Chloride, Glucose, Phosphate, Potassium, Sodium and Urea for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Blood samples were collected for the analysis of clinical chemistry parameters: carbon dioxide, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value. SD=0.00(0) is defined as SD resulted below the detectable limit of the assay and approximate to 0.00(0).

Time frame:
Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · Millimoles per liter
Change From Baseline in Clinical Chemistry Parameters: Carbon Dioxide, Chloride, Glucose, Phosphate, Potassium, Sodium and Urea for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Millimoles per literCAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Carbon dioxide, Month 2-0.4 ± 1.86—
Carbon dioxide, Month 4-0.1 ± 2.00—
Carbon dioxide, Month 8-0.2 ± 2.22—
Carbon dioxide, Month 12-0.7 ± 2.18—
Carbon dioxide, Month 142.0 ± NA—
Carbon dioxide, Month 160.3 ± 2.25—
Carbon dioxide, Month 20-0.2 ± 2.17—
Carbon dioxide, Month 24-0.6 ± 2.12—
Carbon dioxide, Month 261.7 ± 3.27—
Carbon dioxide, Month 280.3 ± 2.61—
Carbon dioxide, Month 301.7 ± 2.73—
Carbon dioxide, Month 320.4 ± 2.43—
Carbon dioxide, Month 340.4 ± 3.13—
Carbon dioxide, Month 360.5 ± 2.46—
Carbon dioxide, Month 381.0 ± 1.41—
Carbon dioxide, Month 401.1 ± 2.63—
Carbon dioxide, Month 420.5 ± 0.71—
Carbon dioxide, Month 440.7 ± 2.61—
Carbon dioxide, Month 460.0 ± 3.74—
Carbon dioxide, Month 480.4 ± 2.25—
Carbon dioxide, Month 501.0 ± 2.83—
Carbon dioxide, Month 521.3 ± 4.32—
Carbon dioxide, LTFU Month 1—1.0 ± 3.39
Carbon dioxide, LTFU Month 3—1.5 ± 2.52
Carbon dioxide, LTFU Month 6—0.7 ± 2.58
Carbon dioxide, LTFU Month 9—1.0 ± 2.97
Carbon dioxide, LTFU Month 12—0.2 ± 2.28
Chloride, Month 21.0 ± 2.06—
Chloride, Month 41.1 ± 2.20—
Chloride, Month 81.2 ± 2.07—
Chloride, Month 121.0 ± 2.24—
Chloride, Month 14-5.0 ± NA—
Chloride, Month 160.3 ± 2.27—
Chloride, Month 200.5 ± 2.52—
Chloride, Month 240.3 ± 2.56—
Chloride, Month 26-2.5 ± 1.97—
Chloride, Month 28-0.3 ± 2.42—
Chloride, Month 30-1.7 ± 2.42—
Chloride, Month 32-0.4 ± 2.31—
Chloride, Month 34-1.8 ± 2.28—
Chloride, Month 36-0.5 ± 2.24—
Chloride, Month 381.0 ± 0.00—
Chloride, Month 40-0.1 ± 2.40—
Chloride, Month 42-2.0 ± 4.24—
Chloride, Month 440.1 ± 2.18—
Chloride, Month 460.5 ± 2.65—
Chloride, Month 48-0.3 ± 2.31—
Chloride, Month 500.0 ± 1.41—
Chloride, Month 52-0.2 ± 2.32—
Chloride, LTFU Month 1—0.6 ± 3.91
Chloride, LTFU Month 3—-1.8 ± 3.30
Chloride, LTFU Month 6—0.2 ± 2.32
Chloride, LTFU Month 9—0.8 ± 2.14
Chloride, LTFU Month 12—-0.2 ± 2.28
Glucose, Month 20.32 ± 0.568—
Glucose, Month 40.42 ± 0.684—
Glucose, Month 80.47 ± 0.842—
Glucose, Month 120.32 ± 0.662—
Glucose, Month 14-1.60 ± NA—
Glucose, Month 160.36 ± 0.754—
Glucose, Month 200.33 ± 0.838—
Glucose, Month 240.19 ± 0.654—
Glucose, Month 26-0.17 ± 1.457—
Glucose, Month 280.30 ± 0.694—
Glucose, Month 30-0.36 ± 0.709—
Glucose, Month 320.34 ± 0.792—
Glucose, Month 340.95 ± 2.475—
Glucose, Month 360.26 ± 0.770—
Glucose, Month 380.20 ± 0.566—
Glucose, Month 400.25 ± 0.929—
Glucose, Month 420.20 ± NA—
Glucose, Month 440.54 ± 1.044—
Glucose, Month 460.40 ± 0.265—
Glucose, Month 480.12 ± 0.593—
Glucose, Month 500.40 ± 0.283—
Glucose, Month 522.10 ± NA—
Glucose, LTFU Month 1—-0.37 ± 0.058
Glucose, LTFU Month 3—-0.45 ± 0.354
Glucose, LTFU Month 6—-0.40 ± 0.627
Glucose, LTFU Month 9—0.02 ± 0.259
Glucose, LTFU Month 12—-0.12 ± 0.084
Phosphate, Month 2-0.00 ± 0.176—
Phosphate, Month 4-0.00 ± 0.191—
Phosphate, Month 8-0.02 ± 0.206—
Phosphate, Month 12-0.02 ± 0.199—
Phosphate, Month 140.25 ± NA—
Phosphate, Month 16-0.02 ± 0.199—
Phosphate, Month 20-0.00 ± 0.227—
Phosphate, Month 24-0.01 ± 0.198—
Phosphate, Month 26-0.14 ± 0.206—
Phosphate, Month 28-0.05 ± 0.216—
Phosphate, Month 300.05 ± 0.268—
Phosphate, Month 32-0.02 ± 0.186—
Phosphate, Month 34-0.02 ± 0.270—
Phosphate, Month 36-0.01 ± 0.192—
Phosphate, Month 38-0.30 ± 0.212—
Phosphate, Month 400.00 ± 0.214—
Phosphate, Month 420.10 ± 0.070—
Phosphate, Month 440.00 ± 0.201—
Phosphate, Month 460.02 ± 0.125—
Phosphate, Month 480.01 ± 0.192—
Phosphate, Month 50-0.20 ± 0.141—
Phosphate, Month 52-0.22 ± 0.216—
Phosphate, LTFU Month 1—-0.03 ± 0.222
Phosphate, LTFU Month 3—0.11 ± 0.225
Phosphate, LTFU Month 6—-0.02 ± 0.175
Phosphate, LTFU Month 9—-0.05 ± 0.165
Phosphate, LTFU Month 12—0.11 ± 0.143
Potassium, Month 20.06 ± 0.392—
Potassium, Month 4-0.02 ± 0.450—
Potassium, Month 80.05 ± 0.408—
Potassium, Month 120.06 ± 0.375—
Potassium, Month 140.00 ± NA—
Potassium, Month 160.00 ± 0.339—
Potassium, Month 200.01 ± 0.374—
Potassium, Month 24-0.04 ± 0.384—
Potassium, Month 260.10 ± 0.228—
Potassium, Month 28-0.09 ± 0.388—
Potassium, Month 300.08 ± 0.293—
Potassium, Month 320.00 ± 0.432—
Potassium, Month 340.18 ± 0.370—
Potassium, Month 36-0.06 ± 0.411—
Potassium, Month 380.35 ± 0.354—
Potassium, Month 40-0.06 ± 0.420—
Potassium, Month 42-0.10 ± 0.424—
Potassium, Month 44-0.04 ± 0.406—
Potassium, Month 46-0.20 ± 0.455—
Potassium, Month 48-0.01 ± 0.374—
Potassium, Month 500.00 ± 0.000—
Potassium, Month 520.17 ± 0.589—
Potassium, LTFU Month 1—0.04 ± 0.313
Potassium, LTFU Month 3—0.10 ± 0.606
Potassium, LTFU Month 6—0.13 ± 0.501
Potassium, LTFU Month 9—0.17 ± 0.873
Potassium, LTFU Month 12—0.10 ± 0.212
Sodium, Month 20.2 ± 1.84—
Sodium, Month 40.6 ± 2.10—
Sodium, Month 80.6 ± 1.96—
Sodium, Month 120.2 ± 1.88—
Sodium, Month 14-3.0 ± NA—
Sodium, Month 160.5 ± 2.02—
Sodium, Month 200.4 ± 1.96—
Sodium, Month 240.5 ± 1.84—
Sodium, Month 260.2 ± 2.32—
Sodium, Month 280.3 ± 2.12—
Sodium, Month 30-0.8 ± 2.14—
Sodium, Month 320.4 ± 2.09—
Sodium, Month 34-0.6 ± 4.72—
Sodium, Month 36-0.1 ± 2.26—
Sodium, Month 381.0 ± 0.00—
Sodium, Month 40-0.1 ± 2.11—
Sodium, Month 42-1.0 ± 1.41—
Sodium, Month 440.2 ± 2.35—
Sodium, Month 460.0 ± 2.94—
Sodium, Month 480.1 ± 1.86—
Sodium, Month 501.0 ± 1.41—
Sodium, Month 522.5 ± 3.15—
Sodium, LTFU Month 1—1.0 ± 1.22
Sodium, LTFU Month 3—-0.5 ± 1.91
Sodium, LTFU Month 6—0.2 ± 0.75
Sodium, LTFU Month 9—0.2 ± 0.75
Sodium, LTFU Month 12—-0.4 ± 0.89
Urea, Month 20.13 ± 1.253—
Urea, Month 4-0.06 ± 1.346—
Urea, Month 80.28 ± 1.131—
Urea, Month 12-0.11 ± 1.318—
Urea, Month 14-0.50 ± NA—
Urea, Month 160.13 ± 1.444—
Urea, Month 200.17 ± 1.332—
Urea, Month 240.15 ± 1.474—
Urea, Month 26-0.92 ± 0.736—
Urea, Month 28-0.01 ± 1.628—
Urea, Month 300.17 ± 1.941—
Urea, Month 320.14 ± 1.419—
Urea, Month 340.50 ± 2.000—
Urea, Month 360.22 ± 1.393—
Urea, Month 381.00 ± 0.707—
Urea, Month 400.27 ± 1.390—
Urea, Month 420.25 ± 1.061—
Urea, Month 440.34 ± 1.475—
Urea, Month 460.63 ± 2.056—
Urea, Month 480.26 ± 1.266—
Urea, Month 500.50 ± 1.414—
Urea, Month 52-0.83 ± 1.211—
Urea, LTFU Month 1—-0.80 ± 0.758
Urea, LTFU Month 3—0.25 ± 0.866
Urea, LTFU Month 6—-1.08 ± 0.861
Urea, LTFU Month 9—-0.17 ± 1.291
Urea, LTFU Month 12—-0.30 ± 0.671
SecondaryChange From Baseline in Clinical Chemistry Parameters: Carbon Dioxide, Chloride, Glucose, Phosphate, Potassium, Sodium and Urea for DTG + RPV Arm up to Month 12 [Maintenance Phase]

Blood samples were collected for the analysis of clinical chemistry parameters: carbon dioxide, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · Millimoles per liter
Change From Baseline in Clinical Chemistry Parameters: Carbon Dioxide, Chloride, Glucose, Phosphate, Potassium, Sodium and Urea for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Millimoles per literDTG + RPV
Carbon dioxide, Month 3-1.0 ± 1.53
Carbon dioxide, Month 6-1.7 ± 1.50
Carbon dioxide, Month 9-1.9 ± 2.85
Carbon dioxide, Month 12-1.9 ± 2.48
Chloride, Month 31.0 ± 1.83
Chloride, Month 61.7 ± 2.14
Chloride, Month 91.0 ± 0.82
Chloride, Month 121.0 ± 2.08
Glucose, Month 30.08 ± 0.259
Glucose, Month 60.16 ± 0.483
Glucose, Month 90.15 ± 0.700
Glucose, Month 120.07 ± 0.55
Phosphate, Month 30.02 ± 0.131
Phosphate, Month 60.08 ± 0.177
Phosphate, Month 90.05 ± 0.178
Phosphate, Month 12-0.05 ± 0.101
Potassium, Month 3-0.26 ± 0.378
Potassium, Month 6-0.03 ± 0.250
Potassium, Month 90.01 ± 0.135
Potassium, Month 12-0.06 ± 0.257
Sodium, Month 30.1 ± 1.68
Sodium, Month 6-0.9 ± 0.90
Sodium, Month 9-1.0 ± 2.58
Sodium, Month 12-1.1 ± 1.07
Urea, Month 31.43 ± 0.732
Urea, Month 61.14 ± 1.144
Urea, Month 91.86 ± 1.994
Urea, Month 120.71 ± 0.756
SecondaryChange From Baseline in Clinical Chemistry Parameters: Cholesterol, High Density Lipoprotein, Cholesterol Direct, Low Density Lipoprotein Cholesterol Calculation, and Cholesterol Direct, Triglycerides for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Blood samples were collected for the analysis of clinical chemistry parameters: cholesterol, direct high density lipoprotein cholesterol, LDL cholesterol calculation, direct low density lipoprotein cholesterol and triglycerides. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · Millimoles per liter
Change From Baseline in Clinical Chemistry Parameters: Cholesterol, High Density Lipoprotein, Cholesterol Direct, Low Density Lipoprotein Cholesterol Calculation, and Cholesterol Direct, Triglycerides for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Millimoles per literCAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Cholesterol, Month 120.12 ± 0.760—
Cholesterol, Month 240.13 ± 0.849—
Cholesterol, Month 260.48 ± 0.569—
Cholesterol, Month 280.00 ± 0.906—
Cholesterol, Month 300.07 ± 1.378—
Cholesterol, Month 32-0.87 ± 0.601—
Cholesterol, Month 340.67 ± 1.378—
Cholesterol, Month 40-0.85 ± 0.804—
Cholesterol, Month 440.27 ± 0.106—
Cholesterol, Month 46-0.10 ± NA—
Cholesterol, Month 48-0.15 ± 0.070—
Cholesterol, LTFU Month 1—-0.87 ± 1.097
Cholesterol, LTFU Month 12—-0.68 ± 1.362
Direct HDL cholesterol, Month 12-0.05 ± 0.224—
Direct HDL cholesterol, Month 24-0.02 ± 0.230—
Direct HDL cholesterol, Month 26-0.05 ± 0.154—
Direct HDL cholesterol, Month 28-0.05 ± 0.241—
Direct HDL cholesterol, Month 300.25 ± 0.141—
Direct HDL cholesterol, Month 32-0.20 ± 0.353—
Direct HDL cholesterol, Month 34-0.07 ± 0.247—
Direct HDL cholesterol, Month 400.08 ± 0.368—
Direct HDL cholesterol, Month 44-0.27 ± 0.247—
Direct HDL cholesterol, Month 46-0.35 ± NA—
Direct HDL cholesterol, Month 48-0.20 ± 0.212—
Direct HDL cholesterol, LTFU Month 1—-0.18 ± 0.213
Direct HDL cholesterol, LTFU Month 12—-0.04 ± 0.290
LDL cholesterol calculation, Month 120.10 ± 0.718—
LDL cholesterol calculation, Month 240.14 ± 0.823—
LDL cholesterol calculation, Month 260.73 ± 0.613—
LDL cholesterol calculation, Month 280.06 ± 0.913—
LDL cholesterol calculation, Month 300.31 ± 2.128—
LDL cholesterol calculation, Month 32-0.30 ± 0.502—
LDL cholesterol calculation, Month 340.95 ± 1.286—
LDL cholesterol calculation, Month 40-0.91 ± 0.202—
LDL cholesterol calculation, Month 44-0.18 ± 0.530—
LDL cholesterol calculation, Month 460.05 ± NA—
LDL cholesterol calculation, Month 48-0.03 ± 0.311—
LDL cholesterol calculation, LTFU Month 1—-0.55 ± 0.989
LDL cholesterol calculation, LTFU Month 12—-0.34 ± 1.510
Direct LDL cholesterol, Month 120.21 ± 0.367—
Direct LDL cholesterol, Month 24-0.23 ± NA—
Triglycerides, Month 120.28 ± 1.965—
Triglycerides, Month 240.20 ± 1.071—
Triglycerides, Month 26-0.20 ± 0.888—
Triglycerides, Month 28-0.02 ± 0.705—
Triglycerides, Month 30-1.06 ± 1.329—
Triglycerides, Month 32-0.80 ± 0.989—
Triglycerides, Month 34-0.43 ± 0.353—
Triglycerides, Month 40-0.04 ± 1.724—
Triglycerides, Month 441.61 ± 0.834—
Triglycerides, Month 460.44 ± NA—
Triglycerides, Month 480.18 ± 0.056—
Triglycerides, LTFU Month 1—-0.29 ± 0.834
Triglycerides, LTFU Month 12—-0.64 ± 1.088
SecondaryAbsolute Values of Clinical Chemistry Parameters: Cholesterol, Direct HDL Cholesterol, LDL Calculation, Direct LDL Cholesterol and Triglycerides for DTG + RPV Arm at Baseline

Blood samples were collected for the analysis of clinical chemistry parameters: cholesterol, HDL cholesterol direct, LDL cholesterol calculation, LDL cholesterol direct and triglycerides.

Time frame:
At Baseline (Day 1)
Reported as:
Mean · Millimoles per liter
Absolute Values of Clinical Chemistry Parameters: Cholesterol, Direct HDL Cholesterol, LDL Calculation, Direct LDL Cholesterol and Triglycerides for DTG + RPV Arm at Baseline
Millimoles per literDTG + RPV
Cholesterol4.88 ± 1.352
Direct HDL cholesterol1.59 ± 0.258
LDL cholesterol calculation2.29 ± 0.52
Direct LDL cholesterol4.45 ± NA
Triglycerides1.52 ± 1.493
SecondaryChange From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted Using CKD-EPI for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Blood samples were collected for the analysis of clinical chemistry parameter: GFR from creatinine adjusted using CKD-EPI. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · Milliliter per minute per 1.73 meter^2
Change From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted Using CKD-EPI for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Milliliter per minute per 1.73 meter^2CAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Month 21.9 ± 7.70—
Month 41.7 ± 10.09—
Month 61.4 ± 7.86—
Month 80.8 ± 8.63—
Month 120.4 ± 9.93—
Month 16-1.7 ± 10.06—
Month 20-0.2 ± 10.69—
Month 24-5.0 ± 11.01—
Month 261.8 ± 5.68—
Month 28-6.5 ± 9.44—
Month 30-12.3 ± 14.47—
Month 32-2.1 ± 9.71—
Month 34-0.5 ± 5.07—
Month 36-2.7 ± 10.12—
Month 38-8.0 ± NA—
Month 400.8 ± 8.56—
Month 42-6.0 ± 7.94—
Month 44-1.9 ± 11.07—
Month 46-8.5 ± 7.78—
Month 48-2.8 ± 9.92—
Month 502.0 ± 7.07—
Month 52-0.5 ± 12.85—
LTFU Month 1—-1.2 ± 9.26
LTFU Month 3—-14.3 ± 10.63
LTFU Month 6—-10.0 ± 14.62
LTFU Month 9—-8.8 ± 9.87
LTFU Month 12—-11.0 ± 7.11
SecondaryChange From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted Using CKD-EPI for DTG + RPV Arm up to Month 12 [Maintenance Phase]

Blood samples were collected for the analysis of clinical chemistry parameter: GFR from creatinine adjusted using CKD-EPI. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · Milliliter per minute per 1.73 meter^2
Change From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted Using CKD-EPI for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Milliliter per minute per 1.73 meter^2DTG + RPV
Month 3-11.7 ± 10.83
Month 6-7.4 ± 4.28
Month 9-16.6 ± 12.27
Month 12-7.3 ± 8.71
SecondaryChange From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted BSA for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Blood samples were collected for the analysis of clinical chemistry parameter: GFR from creatinine adjusted for BSA. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · Milliliter per second per 1.73 meter^2
Change From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted BSA for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Milliliter per second per 1.73 meter^2CAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Month 20.03 ± 0.128—
Month 40.02 ± 0.168—
Month 80.01 ± 0.143—
Month 120.00 ± 0.165—
Month 16-0.02 ± 0.167—
Month 200.00 ± 0.178—
Month 24-0.08 ± 0.183—
Month 260.02 ± 0.094—
Month 28-0.10 ± 0.157—
Month 30-0.20 ± 0.241—
Month 32-0.03 ± 0.161—
Month 340.00 ± 0.084—
Month 36-0.04 ± 0.168—
Month 38-0.13 ± NA—
Month 400.01 ± 0.142—
Month 42-0.10 ± 0.132—
Month 44-0.03 ± 0.184—
Month 46-0.14 ± 0.129—
Month 48-0.04 ± 0.165—
Month 500.03 ± 0.117—
Month 520.00 ± 0.214—
LTFU Month 1—-0.02 ± 0.154
LTFU Month 3—-0.23 ± 0.177
LTFU Month 6—-0.16 ± 0.243
LTFU Month 9—-0.14 ± 0.164
LTFU Month 12—-0.18 ± 0.118
SecondaryChange From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted BSA for DTG + RPV Arm up to Month 12 [Maintenance Phase]

Blood samples were collected for the analysis of clinical chemistry parameter: GFR from creatinine adjusted for BSA. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · Milliliter per second per 1.73 meter^2
Change From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted BSA for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Milliliter per second per 1.73 meter^2DTG + RPV
Month 3-0.19 ± 0.180
Month 6-0.12 ± 0.071
Month 9-0.27 ± 0.204
Month 12-0.12 ± 0.145
SecondaryChange From Baseline in Clinical Chemistry Parameter: Lipase for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Blood samples were collected for the analysis of clinical chemistry parameter: lipase. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · Units per liter
Change From Baseline in Clinical Chemistry Parameter: Lipase for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Units per literCAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Month 2-0.1 ± 29.11—
Month 43.7 ± 47.68—
Month 624.5 ± 64.27—
Month 8-1.3 ± 29.43—
Month 12-2.9 ± 36.83—
Month 16-6.4 ± 31.83—
Month 20-4.0 ± 32.29—
Month 24-2.0 ± 34.89—
Month 2611.0 ± 4.55—
Month 28-1.9 ± 26.19—
Month 30-1.0 ± 14.14—
Month 325.5 ± 56.93—
Month 34-12.8 ± 45.17—
Month 364.9 ± 51.90—
Month 3820.0 ± NA—
Month 400.7 ± 41.09—
Month 42-12.7 ± 27.39—
Month 445.6 ± 40.12—
Month 46-33.3 ± 118.26—
Month 483.7 ± 31.55—
Month 50-3.0 ± 28.28—
Month 523.2 ± 12.24—
LTFU Month 1—27.4 ± 48.97
LTFU Month 3—1.5 ± 10.60
LTFU Month 6—10.8 ± 30.53
LTFU Month 9—3.7 ± 9.40
LTFU Month 12—5.2 ± 6.38
SecondaryChange From Baseline in Clinical Chemistry Parameter: Lipase for DTG + RPV Arm up to Month 12 [Maintenance Phase]

Blood samples were collected for the analysis of clinical chemistry parameter: lipase. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · Units per liter
Change From Baseline in Clinical Chemistry Parameter: Lipase for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Units per literDTG + RPV
Month 32.6 ± 6.90
Month 64.4 ± 4.35
Month 91.3 ± 6.85
Month 1226.0 ± 49.76
SecondaryChange From Baseline in Clinical Chemistry Parameter: Total Cholesterol/ HDL Cholesterol Ratio for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Blood samples were collected for the analysis of clinical chemistry parameter: total cholesterol/ HDL cholesterol ratio. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · Total Cholesterol/HDL Cholesterol Ratio
Change From Baseline in Clinical Chemistry Parameter: Total Cholesterol/ HDL Cholesterol Ratio for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Total Cholesterol/HDL Cholesterol RatioCAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Month 120.20 ± 1.698—
Month 240.05 ± 1.279—
Month 260.55 ± 0.861—
Month 280.11 ± 1.153—
Month 30-1.01 ± 1.630—
Month 32-0.48 ± 1.191—
Month 340.43 ± 0.425—
Month 40-1.09 ± 1.390—
Month 441.65 ± 0.640—
Month 461.37 ± NA—
Month 480.30 ± 0.434—
LTFU Month 1—-0.28 ± 0.916
LTFU Month 12—-0.51 ± 1.078
SecondaryChange From Baseline in Clinical Chemistry Parameter: Total Cholesterol/ HDL Cholesterol Ratio for DTG + RPV Arm at Month 6 [Maintenance Phase]

Blood samples were collected for the analysis of clinical chemistry parameter: total cholesterol/ HDL cholesterol ratio. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
At Month 6 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · Total Cholesterol/HDL Cholesterol Ratio
Change From Baseline in Clinical Chemistry Parameter: Total Cholesterol/ HDL Cholesterol Ratio for DTG + RPV Arm at Month 6 [Maintenance Phase]
Total Cholesterol/HDL Cholesterol RatioDTG + RPV
Change From Baseline in Clinical Chemistry Parameter: Total Cholesterol/ HDL Cholesterol Ratio for DTG + RPV Arm at Month 6 [Maintenance Phase]0.55 ± 0.679
SecondaryChange From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Blood samples were collected for the analysis of hematology parameters: basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · 10^9 cells per liter
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
10^9 cells per literCAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Basophils, Month 2-0.000 ± 0.02200—
Basophils, Month 40.009 ± 0.02913—
Basophils, Month 80.003 ± 0.02524—
Basophils, Month 12-0.003 ± 0.02501—
Basophils, Month 160.003 ± 0.02629—
Basophils, Month 200.003 ± 0.02751—
Basophils, Month 22-0.020 ± 0.04243—
Basophils, Month 240.001 ± 0.02306—
Basophils, Month 26-0.004 ± 0.01673—
Basophils, Month 280.008 ± 0.02919—
Basophils, Month 300.007 ± 0.03862—
Basophils, Month 320.003 ± 0.02567—
Basophils, Month 34-0.010 ± 0.01000—
Basophils, Month 36-0.001 ± 0.03325—
Basophils, Month 380.000 ± 0.01414—
Basophils, Month 400.004 ± 0.02461—
Basophils, Month 420.000 ± 0.03606—
Basophils, Month 44-0.001 ± 0.02271—
Basophils, Month 460.005 ± 0.02121—
Basophils, Month 48-0.002 ± 0.02682—
Basophils, Month 50-0.045 ± 0.04950—
Basophils, Month 520.021 ± 0.02858—
Basophils, LTFU Month 1—0.004 ± 0.02702
Basophils, LTFU Month 3—0.000 ± 0.02944
Basophils, LTFU Month 6—-0.001 ± 0.03764
Basophils, LTFU Month 9—0.000 ± 0.02000
Basophils, LTFU Month 12—0.010 ± 0.03240
Eosinophils, Month 20.017 ± 0.11886—
Eosinophils, Month 40.004 ± 0.12341—
Eosinophils, Month 80.003 ± 0.14555—
Eosinophils, Month 12-0.000 ± 0.13671—
Eosinophils, Month 16-0.002 ± 0.12115—
Eosinophils, Month 20-0.004 ± 0.11308—
Eosinophils, Month 220.005 ± 0.00707—
Eosinophils, Month 24-0.021 ± 0.10959—
Eosinophils, Month 260.014 ± 0.04393—
Eosinophils, Month 28-0.021 ± 0.12165—
Eosinophils, Month 300.072 ± 0.09878—
Eosinophils, Month 32-0.009 ± 0.15093—
Eosinophils, Month 340.083 ± 0.11846—
Eosinophils, Month 36-0.020 ± 0.13447—
Eosinophils, Month 380.070 ± 0.21213—
Eosinophils, Month 40-0.014 ± 0.14536—
Eosinophils, Month 420.146 ± 0.04933—
Eosinophils, Month 44-0.023 ± 0.12973—
Eosinophils, Month 460.065 ± 0.02121—
Eosinophils, Month 48-0.016 ± 0.13128—
Eosinophils, Month 50-0.085 ± 0.19092—
Eosinophils, Month 52-0.020 ± 0.09675—
Eosinophils, LTFU Month 1—-0.006 ± 0.03847
Eosinophils, LTFU Month 3—-0.042 ± 0.02062
Eosinophils, LTFU Month 6—0.015 ± 0.05925
Eosinophils, LTFU Month 9—-0.041 ± 0.04535
Eosinophils, LTFU Month 12—0.036 ± 0.04930
Leukocytes, Month 2-0.054 ± 1.1875—
Leukocytes, Month 40.276 ± 1.4416—
Leukocytes, Month 80.257 ± 1.4252—
Leukocytes, Month 12-0.153 ± 1.1961—
Leukocytes, Month 160.333 ± 1.4322—
Leukocytes, Month 200.069 ± 1.2588—
Leukocytes, Month 22-0.050 ± 0.4950—
Leukocytes, Month 240.247 ± 1.3444—
Leukocytes, Month 26-0.700 ± 0.9220—
Leukocytes, Month 280.369 ± 1.2534—
Leukocytes, Month 300.775 ± 1.1147—
Leukocytes, Month 320.582 ± 1.5079—
Leukocytes, Month 34-0.033 ± 0.6351—
Leukocytes, Month 360.197 ± 1.3119—
Leukocytes, Month 380.450 ± 2.3335—
Leukocytes, Month 400.111 ± 1.4863—
Leukocytes, Month 420.750 ± 1.6299—
Leukocytes, Month 440.016 ± 1.4332—
Leukocytes, Month 460.700 ± 0.2828—
Leukocytes, Month 480.237 ± 1.3630—
Leukocytes, Month 50-2.650 ± 1.2021—
Leukocytes, Month 520.950 ± 0.6804—
Leukocytes, LTFU Month 1—0.740 ± 1.1327
Leukocytes, LTFU Month 3—1.100 ± 1.4720
Leukocytes, LTFU Month 6—-0.067 ± 1.0820
Leukocytes, LTFU Month 9—-0.317 ± 0.5529
Leukocytes, LTFU Month 12—-0.240 ± 0.7369
Lymphocytes, Month 20.116 ± 0.44032—
Lymphocytes, Month 40.150 ± 0.42751—
Lymphocytes, Month 80.100 ± 0.49306—
Lymphocytes, Month 120.022 ± 0.61142—
Lymphocytes, Month 160.144 ± 0.50914—
Lymphocytes, Month 200.197 ± 0.49264—
Lymphocytes, Month 220.815 ± 0.82731—
Lymphocytes, Month 240.184 ± 0.53796—
Lymphocytes, Month 260.064 ± 0.30262—
Lymphocytes, Month 280.269 ± 0.50159—
Lymphocytes, Month 300.657 ± 0.34219—
Lymphocytes, Month 320.294 ± 0.54583—
Lymphocytes, Month 340.260 ± 0.58813—
Lymphocytes, Month 360.176 ± 0.53181—
Lymphocytes, Month 380.185 ± 0.71418—
Lymphocytes, Month 400.193 ± 0.51843—
Lymphocytes, Month 420.990 ± 0.23388—
Lymphocytes, Month 440.090 ± 0.55940—
Lymphocytes, Month 46-0.375 ± 0.86974—
Lymphocytes, Month 480.225 ± 0.55785—
Lymphocytes, Month 50-0.765 ± 0.54447—
Lymphocytes, Month 520.580 ± 0.26967—
Lymphocytes, LTFU Month 1—0.316 ± 0.68995
Lymphocytes, LTFU Month 3—0.215 ± 0.31268
Lymphocytes, LTFU Month 6—0.018 ± 0.40276
Lymphocytes, LTFU Month 9—-0.013 ± 0.33339
Lymphocytes, LTFU Month 12—0.182 ± 0.43906
Monocytes, Month 20.022 ± 0.11715—
Monocytes, Month 40.048 ± 0.14689—
Monocytes, Month 80.026 ± 0.16979—
Monocytes, Month 12-0.021 ± 0.15241—
Monocytes, Month 160.060 ± 0.14219—
Monocytes, Month 200.032 ± 0.15386—
Monocytes, Month 220.060 ± 0.11314—
Monocytes, Month 240.039 ± 0.15115—
Monocytes, Month 26-0.012 ± 0.08585—
Monocytes, Month 280.093 ± 0.15913—
Monocytes, Month 300.105 ± 0.11328—
Monocytes, Month 320.030 ± 0.13926—
Monocytes, Month 34-0.060 ± 0.06557—
Monocytes, Month 360.016 ± 0.16850—
Monocytes, Month 380.195 ± 0.12021—
Monocytes, Month 400.037 ± 0.17293—
Monocytes, Month 420.230 ± 0.11358—
Monocytes, Month 440.003 ± 0.14568—
Monocytes, Month 460.020 ± 0.08485—
Monocytes, Month 480.026 ± 0.13077—
Monocytes, Month 50-0.085 ± 0.23335—
Monocytes, Month 520.198 ± 0.13556—
Monocytes, LTFU Month 1—-0.020 ± 0.06245
Monocytes, LTFU Month 3—-0.007 ± 0.13451
Monocytes, LTFU Month 6—0.038 ± 0.09621
Monocytes, LTFU Month 9—-0.031 ± 0.09283
Monocytes, LTFU Month 12—0.008 ± 0.05541
Neutrophils, Month 2-0.197 ± 0.99349—
Neutrophils, Month 40.056 ± 1.19574—
Neutrophils, Month 80.120 ± 1.18605—
Neutrophils, Month 12-0.134 ± 1.03311—
Neutrophils, Month 160.129 ± 1.23997—
Neutrophils, Month 20-0.158 ± 1.09672—
Neutrophils, Month 22-0.890 ± 1.14551—
Neutrophils, Month 240.019 ± 1.06166—
Neutrophils, Month 26-0.788 ± 0.92394—
Neutrophils, Month 280.025 ± 1.10870—
Neutrophils, Month 30-0.065 ± 0.70174—
Neutrophils, Month 320.265 ± 1.45710—
Neutrophils, Month 34-0.310 ± 0.32187—
Neutrophils, Month 360.027 ± 1.15025—
Neutrophils, Month 38-0.005 ± 1.70413—
Neutrophils, Month 40-0.100 ± 1.23231—
Neutrophils, Month 420.000 ± 1.35532—
Neutrophils, Month 44-0.049 ± 1.19998—
Neutrophils, Month 461.015 ± 1.30815—
Neutrophils, Month 480.005 ± 1.16199—
Neutrophils, Month 50-1.665 ± 1.26572—
Neutrophils, Month 520.151 ± 0.58952—
Neutrophils, LTFU Month 1—0.448 ± 0.47694
Neutrophils, LTFU Month 3—0.932 ± 1.35866
Neutrophils, LTFU Month 6—-0.148 ± 0.90442
Neutrophils, LTFU Month 9—-0.238 ± 0.37408
Neutrophils, LTFU Month 12—-0.462 ± 0.51611
Platelets, Month 23.77 ± 23.389—
Platelets, Month 45.40 ± 30.889—
Platelets, Month 83.74 ± 24.695—
Platelets, Month 121.14 ± 32.005—
Platelets, Month 168.37 ± 34.613—
Platelets, Month 204.19 ± 33.235—
Platelets, Month 22-10.50 ± 24.749—
Platelets, Month 245.36 ± 29.747—
Platelets, Month 2631.00 ± 34.728—
Platelets, Month 287.05 ± 36.502—
Platelets, Month 3010.00 ± 41.873—
Platelets, Month 3216.29 ± 43.183—
Platelets, Month 3424.67 ± 28.024—
Platelets, Month 3618.09 ± 40.388—
Platelets, Month 389.50 ± 38.891—
Platelets, Month 4012.52 ± 33.756—
Platelets, Month 4218.50 ± 9.434—
Platelets, Month 4421.07 ± 40.846—
Platelets, Month 4628.50 ± 14.849—
Platelets, Month 4816.70 ± 38.627—
Platelets, Month 50-2.50 ± 7.778—
Platelets, Month 5222.50 ± 54.357—
Platelets, LTFU Month 1—10.80 ± 25.762
Platelets, LTFU Month 3—7.25 ± 19.973
Platelets, LTFU Month 6—-8.00 ± 24.503
Platelets, LTFU Month 9—-13.50 ± 37.877
Platelets, LTFU Month 12—0.80 ± 22.709
SecondaryChange From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets for DTG + RPV Arm up to Month 12 [Maintenance Phase]

Blood samples were collected for the analysis of hematology parameters: basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · 10^9 cells per liter
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets for DTG + RPV Arm up to Month 12 [Maintenance Phase]
10^9 cells per literDTG + RPV
Basophils, Month 3-0.008 ± 0.01464
Basophils, Month 6-0.010 ± 0.02309
Basophils, Month 9-0.005 ± 0.01512
Basophils, Month 12-0.010 ± 0.01732
Eosinophils, Month 3-0.072 ± 0.16307
Eosinophils, Month 6-0.057 ± 0.11236
Eosinophils, Month 9-0.051 ± 0.10040
Eosinophils, Month 12-0.030 ± 0.17127
Leukocytes, Month 30.014 ± 0.7669
Leukocytes, Month 6-0.386 ± 0.8355
Leukocytes, Month 90.014 ± 1.3508
Leukocytes, Month 12-0.057 ± 0.9343
Lymphocytes, Month 30.053 ± 0.43811
Lymphocytes, Month 6-0.019 ± 0.35435
Lymphocytes, Month 90.085 ± 0.59379
Lymphocytes, Month 12-0.001 ± 0.39121
Monocytes, Month 30.098 ± 0.08877
Monocytes, Month 60.020 ± 0.07211
Monocytes, Month 9-0.021 ± 0.06644
Monocytes, Month 120.004 ± 0.07435
Neutrophils, Month 30.097 ± 0.47612
Neutrophils, Month 6-0.295 ± 0.64143
Neutrophils, Month 90.115 ± 1.20803
Neutrophils, Month 12-0.034 ± 0.80715
Platelets, Month 3-1.00 ± 18.841
Platelets, Month 6-12.57 ± 35.298
Platelets, Month 9-21.29 ± 61.372
Platelets, Month 12-2.86 ± 47.544
SecondaryChange From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Blood samples were collected for the analysis of hematology parameter: erythrocytes mean corpuscular volume. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · Femtoliters
Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
FemtolitersCAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Month 2-1.07 ± 1.731—
Month 4-2.04 ± 2.186—
Month 8-1.42 ± 2.527—
Month 12-1.28 ± 2.528—
Month 16-2.91 ± 2.379—
Month 20-1.93 ± 2.544—
Month 222.00 ± 4.243—
Month 24-1.35 ± 2.985—
Month 26-2.60 ± 0.894—
Month 28-3.18 ± 2.918—
Month 30-6.75 ± 2.500—
Month 32-2.77 ± 3.355—
Month 34-3.67 ± 3.512—
Month 36-1.78 ± 2.592—
Month 38-1.50 ± 0.707—
Month 40-3.71 ± 3.217—
Month 42-6.75 ± 2.630—
Month 44-2.84 ± 3.167—
Month 460.50 ± 2.121—
Month 48-2.30 ± 3.339—
Month 50-1.00 ± 2.828—
Month 52-4.00 ± 3.847—
LTFU Month 1—-3.20 ± 3.962
LTFU Month 3—-4.00 ± 3.742
LTFU Month 6—-0.83 ± 4.167
LTFU Month 9—-1.33 ± 4.457
LTFU Month 12—-1.60 ± 6.504
SecondaryChange From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume for DTG + RPV Arm up to Month 12 [Maintenance Phase]

Blood samples were collected for the analysis of hematology parameter: erythrocytes mean corpuscular volume. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · Femtoliters
Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume for DTG + RPV Arm up to Month 12 [Maintenance Phase]
FemtolitersDTG + RPV
Month 3-1.00 ± 1.000
Month 60.14 ± 1.574
Month 90.29 ± 1.704
Month 12-0.14 ± 1.952
SecondaryChange From Baseline in Hematology Parameter: Erythrocytes for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Blood samples were collected for the analysis of hematology parameter: erythrocytes. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value. SD=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.

Time frame:
Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · 10^12 cells per liter
Change From Baseline in Hematology Parameter: Erythrocytes for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
10^12 cells per literCAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Month 2-0.064 ± 0.2773—
Month 4-0.021 ± 0.3185—
Month 8-0.085 ± 0.3164—
Month 12-0.063 ± 0.3279—
Month 16-0.034 ± 0.3014—
Month 20-0.020 ± 0.2754—
Month 22-0.450 ± 0.0707—
Month 24-0.061 ± 0.3181—
Month 260.020 ± 0.1924—
Month 28-0.113 ± 0.2949—
Month 30-0.075 ± 0.0500—
Month 32-0.087 ± 0.3801—
Month 34-0.233 ± 0.1155—
Month 36-0.090 ± 0.3591—
Month 38-0.350 ± 0.3536—
Month 40-0.056 ± 0.3528—
Month 420.025 ± 0.4272—
Month 44-0.072 ± 0.4086—
Month 46-0.100 ± 0.1414—
Month 48-0.090 ± 0.3196—
Month 50-0.300 ± 0.0000—
Month 52-0.200 ± 0.5177—
LTFU Month 1—-0.160 ± 0.2408
LTFU Month 3—0.075 ± 0.2217
LTFU Month 6—-0.250 ± 0.2811
LTFU Month 9—-0.433 ± 0.2944
LTFU Month 12—-0.160 ± 0.4722
SecondaryChange From Baseline in Hematology Parameter: Erythrocytes for DTG + RPV Arm up to Month 12 [Maintenance Phase]

Blood samples were collected for the analysis of hematology parameter: erythrocytes. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · 10^12 cells per liter
Change From Baseline in Hematology Parameter: Erythrocytes for DTG + RPV Arm up to Month 12 [Maintenance Phase]
10^12 cells per literDTG + RPV
Month 3-0.114 ± 0.1464
Month 6-0.171 ± 0.1113
Month 9-0.171 ± 0.1704
Month 12-0.143 ± 0.0976
SecondaryChange From Baseline in Hematology Parameter: Hematocrit for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematology Parameter: Hematocrit for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Proportion of red blood cells in bloodCAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Month 2-0.011 ± 0.02762—
Month 4-0.012 ± 0.02935—
Month 8-0.015 ± 0.02809—
Month 12-0.011 ± 0.02760—
Month 16-0.017 ± 0.02824—
Month 20-0.011 ± 0.02731—
Month 22-0.032 ± 0.00707—
Month 24-0.012 ± 0.02668—
Month 26-0.010 ± 0.01723—
Month 28-0.026 ± 0.02663—
Month 30-0.040 ± 0.00822—
Month 32-0.022 ± 0.03499—
Month 34-0.037 ± 0.01442—
Month 36-0.017 ± 0.03340—
Month 38-0.034 ± 0.02192—
Month 40-0.023 ± 0.03088—
Month 42-0.025 ± 0.03938—
Month 44-0.021 ± 0.03702—
Month 46-0.006 ± 0.00353—
Month 48-0.019 ± 0.03114—
Month 50-0.033 ± 0.01697—
Month 52-0.041 ± 0.04229—
LTFU Month 1—-0.028 ± 0.01864
LTFU Month 3—-0.012 ± 0.02102
LTFU Month 6—-0.027 ± 0.03065
LTFU Month 9—-0.044 ± 0.02265
LTFU Month 12—-0.022 ± 0.03928
SecondaryChange From Baseline in Hematology Parameter: Hematocrit for DTG + RPV Arm up to Month 12 [Maintenance Phase]

Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematology Parameter: Hematocrit for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Proportion of red blood cells in bloodDTG + RPV
Month 3-0.015 ± 0.01516
Month 6-0.013 ± 0.01287
Month 9-0.013 ± 0.01332
Month 12-0.013 ± 0.01491
SecondaryChange From Baseline in Hematology Parameter: Hemoglobin for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase

Blood samples were collected for the analysis of hematology parameter: hemoglobin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Mean · Grams per liter
Change From Baseline in Hematology Parameter: Hemoglobin for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Grams per literCAB LA + RPV LA Q2MLTFU: CAB LA+RPV LA Q2M Group
Month 2-2.11 ± 8.801—
Month 4-1.57 ± 9.433—
Month 8-3.29 ± 8.542—
Month 12-3.19 ± 8.814—
Month 16-3.44 ± 8.293—
Month 20-2.30 ± 8.054—
Month 22-13.00 ± 1.414—
Month 24-3.35 ± 8.671—
Month 260.60 ± 6.804—
Month 28-4.06 ± 8.281—
Month 30-4.00 ± 4.243—
Month 32-4.13 ± 11.183—
Month 34-8.33 ± 3.215—
Month 36-4.86 ± 10.749—
Month 38-8.50 ± 6.364—
Month 40-4.51 ± 9.701—
Month 42-3.50 ± 11.358—
Month 44-6.27 ± 11.766—
Month 46-6.50 ± 2.121—
Month 48-7.41 ± 9.341—
Month 50-9.00 ± 9.899—
Month 52-6.67 ± 11.605—
LTFU Month 1—-3.40 ± 7.956
LTFU Month 3—1.50 ± 3.697
LTFU Month 6—-4.67 ± 9.993
LTFU Month 9—-10.00 ± 6.000
LTFU Month 12—-1.20 ± 14.464
SecondaryChange From Baseline in Hematology Parameter: Hemoglobin for DTG + RPV Arm up to Month 12 [Maintenance Phase]

Blood samples were collected for the analysis of hematology parameter: hemoglobin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · Grams per liter
Change From Baseline in Hematology Parameter: Hemoglobin for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Grams per literDTG + RPV
Month 3-3.57 ± 6.554
Month 6-4.29 ± 2.928
Month 9-4.86 ± 3.891
Month 12-4.57 ± 5.062
SecondaryUrine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio

Urine samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio.

Time frame:
At Baseline (Day 1)
Reported as:
Mean · Ratio
Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio
RatioCAB LA + RPV LA Q2MDTG + RPV
Urine albumin/creatinine ratio0.7 ± 0.9800.4 ± 0.122
Urine protein/creatinine ratio7.6 ± 4.5289.1 ± 7.237
SecondaryAbsolute Values of Urine Creatinine

Urine samples were collected for the analysis of urine creatinine.

Time frame:
At Baseline (Day 1)
Reported as:
Mean · Micromoles per liter
Absolute Values of Urine Creatinine
Micromoles per literCAB LA + RPV LA Q2MDTG + RPV
Absolute Values of Urine Creatinine14875.6 ± 9267.9512112.9 ± 7186.16
SecondaryAbsolute Values of Urine Phosphate

Urine samples were collected for the analysis of urine phosphate.

Time frame:
At Baseline (Day 1)
Reported as:
Mean · Millimoles per liter
Absolute Values of Urine Phosphate
Millimoles per literCAB LA + RPV LA Q2MDTG + RPV
Absolute Values of Urine Phosphate18.2 ± 15.30614.7 ± 6.917
SecondaryAbsolute Values of Urine Specific Gravity

Urine samples were collected for the analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.

Time frame:
At Baseline (Day 1)
Reported as:
Mean · Ratio
Absolute Values of Urine Specific Gravity
RatioCAB LA + RPV LA Q2MDTG + RPV
Absolute Values of Urine Specific Gravity1.0 ± 0.0071.0 ± 0.007
SecondaryAbsolute Values of Urine Potential of Hydrogen (pH)

Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0).

Time frame:
At Baseline (Day 1)
Reported as:
Mean · pH
Absolute Values of Urine Potential of Hydrogen (pH)
pHCAB LA + RPV LA Q2MDTG + RPV
Absolute Values of Urine Potential of Hydrogen (pH)6.1 ± 0.7396.5 ± 0.345
SecondaryNumber of Participants With Treatment Emergent Genotypic Resistance

Plasma samples were collected and analyzed for genotypic resistance from participants who met confirmed virologic withdrawal criteria.

Time frame:
Up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Genotypic Resistance
ParticipantsCAB LA + RPV LA Q2MDTG + RPV
Number of Participants With Treatment Emergent Genotypic Resistance0—
SecondaryNumber of Participants With Treatment Emergent Phenotypic Resistance

Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria.

Time frame:
Up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Phenotypic Resistance
ParticipantsCAB LA + RPV LA Q2MDTG + RPV
Number of Participants With Treatment Emergent Phenotypic Resistance0—
SecondaryChange From Baseline in HIV Dependent Quality of Life (HIVDQoL - Self-completion Questionnaire Designed to Measure QoL in People Living With HIV)

HIVDQoL includes 2 overview items and 26 domain items. The 2 overview items: Item 1: 3(excellent) to -3(extremely bad); Higher score indicates better quality of life. Item 2: -3(very much better) to 1(worse); Lower score indicates better quality of life. The Weighted Impact Score (WIS) was calculated for the 26 domain items by multiplying impact score(IS) (-3\[maximum {max.} negative impact\] to +1\[max. positive impact\] by the corresponding importance score (3 \[very important\] to 0\[not all important\]). Average Weighted Impact (AWI) score was calculated by summing individual weighted IS and dividing by the number of domain items. The ranges of WIS and average IS were from -9(max. negative) to +3(max. positive);higher score indicates positive impact. Change from Baseline was defined as post-dose visit value minus Baseline value (latest pre-treatment assessment with a non-missing value). SD=0.00 is defined as SD resulted below the detectable limit of the assay and approximate to 0.00.

Time frame:
At Months 6 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · Scores on a scale
Change From Baseline in HIV Dependent Quality of Life (HIVDQoL - Self-completion Questionnaire Designed to Measure QoL in People Living With HIV)
Scores on a scaleCAB LA + RPV LA Q2MDTG + RPV
Overview Item 1, Month 60.1 ± 0.650.4 ± 0.53
Overview Item 1, Month 120.0 ± 0.75-0.1 ± 0.38
Overview Item 2, Month 60.0 ± 1.110.3 ± 1.25
Overview Item 2, Month 120.2 ± 1.05-0.6 ± 1.13
Leisure, Month 60.1 ± 2.200.9 ± 1.46
Leisure, Month 120.2 ± 2.02-1.6 ± 3.74
Work, Month 6-0.3 ± 2.07-0.9 ± 4.14
Work, Month 12-0.1 ± 2.48-0.7 ± 2.75
Holiday, Month 6-0.5 ± 2.24-0.3 ± 3.55
Holiday, Month 12-0.1 ± 2.76-2.0 ± 2.83
Getting out and about, Month 60.0 ± 1.83-1.1 ± 3.76
Getting out and about, Month 12-0.2 ± 2.01-1.9 ± 2.48
Long journey, Month 60.3 ± 2.24-0.4 ± 2.70
Long journey, Month 120.4 ± 2.45-2.3 ± 2.93
Do Physically, Month 6-0.2 ± 2.09-0.7 ± 2.36
Do Physically, Month 12-0.3 ± 2.39-1.7 ± 2.63
Family, Month 6-0.1 ± 1.38-0.9 ± 2.27
Family, Month 12-0.3 ± 2.30-1.5 ± 2.51
Friends, Month 6-0.7 ± 1.93-1.1 ± 2.85
Friends, Month 12-0.3 ± 2.57-2.0 ± 2.38
Go on dates, Month 6-0.4 ± 2.04-3.5 ± 3.54
Go on dates, Month 12-0.2 ± 3.11-3.5 ± 3.54
Close relationships, Month 60.4 ± 3.10-0.5 ± 2.95
Close relationships, Month 120.2 ± 3.13-0.5 ± 2.95
Sex life, Month 60.2 ± 2.74-1.3 ± 2.80
Sex life, Month 12-0.2 ± 2.62-1.0 ± 3.00
Physical appearance, Month 6-0.3 ± 1.78-1.1 ± 2.85
Physical appearance, Month 12-0.2 ± 2.28-1.4 ± 2.23
Self-confidence, Month 60.0 ± 2.35-1.7 ± 2.43
Self-confidence, Month 120.2 ± 2.83-2.9 ± 3.48
Motivation, Month 6-0.3 ± 2.04-0.6 ± 2.51
Motivation, Month 12-0.3 ± 2.85-2.1 ± 2.85
Stigma, Month 6-1.1 ± 2.38—
Stigma, Month 120.0 ± 3.03-2.0 ± NA
Conceal, Month 6-0.6 ± 2.91-1.6 ± 3.51
Conceal, Month 120.3 ± 3.04-0.4 ± 4.10
Feelings About the Future, Month 60.0 ± 2.891.0 ± 2.24
Feelings About the Future, Month 120.3 ± 3.02-0.9 ± 2.85
Financial Situation, Month 6-0.1 ± 2.761.1 ± 1.46
Financial Situation, Month 12-0.1 ± 2.59-0.6 ± 4.61
Depend on Others, Month 6-0.4 ± 3.110.0 ± 0.00
Depend on Others, Month 12-0.2 ± 2.73-1.2 ± 3.25
Others Fuss or Worry, Month 60.0 ± 3.00-1.6 ± 3.36
Others Fuss or Worry, Month 120.1 ± 3.21-0.3 ± 3.50
Freedom to Eat, Month 60.0 ± 1.98-1.3 ± 3.40
Freedom to Eat, Month 120.1 ± 2.62-1.1 ± 2.48
Freedom to Drink, Month 6-0.2 ± 1.81-0.7 ± 4.42
Freedom to Drink, Month 12-0.1 ± 2.47-1.7 ± 3.40
Spiritual/Religious Life, Month 6-0.1 ± 2.46-0.5 ± 1.22
Spiritual/Religious Life, Month 12-0.1 ± 1.14-1.0 ± 2.45
Feelings About the Past, Month 6-0.3 ± 2.690.7 ± 2.21
Feelings About the Past, Month 120.0 ± 2.74-1.3 ± 2.21
Having Children or More Children, Month 60.3 ± 1.861.3 ± 4.27
Having Children or More Children, Month 12-0.3 ± 2.82-1.5 ± 3.00
Sleep, Month 6-0.2 ± 2.320.7 ± 1.25
Sleep, Month 120.0 ± 2.56-0.4 ± 2.70
Average Weighted Impact, Month 6-0.17 ± 1.084-0.43 ± 1.792
Average Weighted Impact, Month 12-0.07 ± 1.690-1.27 ± 1.695
SecondaryChange From Baseline in Total Treatment Satisfaction Score of HIV Treatment Satisfaction Status Questionnaire (HIVTSQs)

HIVTSQs total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range of 0 to 66. Higher the score, greater improvement in satisfaction with treatment as compared to the past few weeks; lower score, greater the deterioration in satisfaction with treatment. A score of 0 represents no change. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.

Time frame:
At Months 6 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · Scores on a scale
Change From Baseline in Total Treatment Satisfaction Score of HIV Treatment Satisfaction Status Questionnaire (HIVTSQs)
Scores on a scaleCAB LA + RPV LA Q2MDTG + RPV
Month 6-0.19 ± 6.4190.71 ± 3.773
Month 12-0.42 ± 6.6590.14 ± 6.256
SecondaryChange From Baseline in Individual Item Score of HIVTSQs

HIVTSQs is a 12 item questionnaire. The individual item scores are rated as 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater treatment satisfaction as compared to the past few weeks. Change from Baseline is defined as post-dose value minus Baseline value. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. SD=0.00 is defined as SD resulted below the detectable limit of the assay and approximate to 0.00.

Time frame:
At Months 6 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · Scores on a scale
Change From Baseline in Individual Item Score of HIVTSQs
Scores on a scaleCAB LA + RPV LA Q2MDTG + RPV
Item 1, Month 6-0.1 ± 0.820.0 ± 0.00
Item 1, Month 12-0.1 ± 0.75-0.1 ± 0.38
Item 2, Month 6-0.1 ± 0.46-0.3 ± 0.49
Item 2, Month 120.0 ± 0.34-0.1 ± 0.38
Item 3, Month 6-0.5 ± 1.410.1 ± 0.38
Item 3, Month 12-0.5 ± 1.21-0.1 ± 0.38
Item 4, Month 60.0 ± 0.950.0 ± 0.00
Item 4, Month 120.1 ± 0.930.1 ± 0.69
Item 5, Month 60.1 ± 1.000.3 ± 0.49
Item 5, Month 120.1 ± 1.140.1 ± 0.38
Item 6, Month 60.1 ± 1.130.4 ± 1.62
Item 6, Month 120.0 ± 1.310.3 ± 1.80
Item 7, Month 60.1 ± 0.740.0 ± 0.58
Item 7, Month 120.0 ± 1.060.1 ± 0.69
Item 8, Month 60.2 ± 0.930.0 ± 0.58
Item 8, Month 120.1 ± 0.950.0 ± 0.58
Item 9, Month 6-0.1 ± 0.610.0 ± 0.00
Item 9, Month 12-0.2 ± 0.80-0.1 ± 0.38
Item 10, Month 60.1 ± 0.910.3 ± 0.76
Item 10, Month 120.1 ± 1.030.1 ± 0.90
Item 11, Month 60.0 ± 1.09-0.1 ± 0.38
Item 11, Month 120.1 ± 0.79-0.1 ± 0.90
Item 12, Month 6-1.3 ± 1.59-0.6 ± 1.13
Item 12, Month 12-1.1 ± 1.58-0.1 ± 0.38
SecondaryChange in Treatment Satisfaction Over Time Using the HIV Treatment Satisfaction Change Questionnaire (HIVTSQc)

HIVTSQc (change version) total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range:-33 to 33. Higher scores represent greater improvement in treatment satisfaction compared to satisfaction with treatment received during the induction phase; lower scores represented deterioration in satisfaction with treatment. A score of 0 represents no change. A maximum of 5 items can be missing, the missing scores were imputed with the mean of the completed item scores. If 6 or more items are missing, then the overall treatment satisfaction scale score was not computed and remained missing.

Time frame:
At Month 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Reported as:
Mean · Scores on a scale
Change in Treatment Satisfaction Over Time Using the HIV Treatment Satisfaction Change Questionnaire (HIVTSQc)
Scores on a scaleCAB LA + RPV LA Q2MDTG + RPV
Change in Treatment Satisfaction Over Time Using the HIV Treatment Satisfaction Change Questionnaire (HIVTSQc)28.0 ± 6.7827.7 ± 6.97
Other pre-specifiedPlasma Trough Concentration (Ctrough) for CAB LA

Blood samples were collected at indicated time points for pharmacokinetic analysis of CAB LA. This was a conditional secondary endpoint for which results are not available because the trough concentrations for this product are well characterized and therefore, secondary population pharmacokinetic (Pop PK) analyses were not conducted.

Time frame:
Pre-dose (Day 1) and Month 12 [Maintenance Phase]

No measurements were reported for this outcome.

Other pre-specifiedCtrough for RPV LA

Blood samples were collected at indicated time points for pharmacokinetic analysis of RPV LA. This was a conditional secondary endpoint for which results are not available because the trough concentrations for this product are well characterized and therefore, secondary Pop PK analyses were not conducted.

Time frame:
Pre-dose (Day 1) and Month 12 [Maintenance Phase]

No measurements were reported for this outcome.

Adverse events

Collected over Non-Serious adverse events (Other Adverse events (AEs)) and Serious adverse events (SAE) were collected from Day 1 and up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase, up to a maximum of 52 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CAB LA + RPV LA Q2M0/90 (0%)10/90 (11.1%)86/90 (95.6%)
DTG + RPV0/7 (0%)0/7 (0%)3/7 (42.9%)
LTFU: CAB LA+RPV LA Q2M Group0/6 (0%)0/6 (0%)0/6 (0%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventCAB LA + RPV LA Q2MDTG + RPVLTFU: CAB LA+RPV LA Q2M Group
Cholecystitis acuteHepatobiliary disorders1/900/70/6
CholelithiasisHepatobiliary disorders1/900/70/6
Anal abscessInfections and infestations1/900/70/6
OrchitisInfections and infestations1/900/70/6
Urinary tract infection bacterialInfections and infestations1/900/70/6
ProctitisGastrointestinal disorders1/900/70/6
Injection site extravasationGeneral disorders1/900/70/6
COVID-19 pneumoniaInfections and infestations1/900/70/6
CellulitisInfections and infestations1/900/70/6
Staphylococcal infectionInfections and infestations1/900/70/6
Most frequent other events
Showing 10 of 33
Most frequent other events
EventCAB LA + RPV LA Q2MDTG + RPVLTFU: CAB LA+RPV LA Q2M Group
Injection site painGeneral disorders67/900/70/6
COVID-19Infections and infestations30/900/70/6
Upper respiratory tract infectionInfections and infestations16/900/70/6
PyrexiaGeneral disorders14/900/70/6
NasopharyngitisInfections and infestations14/900/70/6
Injection site discomfortGeneral disorders13/900/70/6
SyphilisInfections and infestations13/900/70/6
DiarrhoeaGastrointestinal disorders13/900/70/6
Abdominal painGastrointestinal disorders2/901/70/6
HeadacheNervous system disorders9/901/70/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)CAB LA + RPV LA Q2MDTG + RPVTotal
Overall Study41.2 ± 9.4949.1 ± 11.4241.7 ± 9.80
Sex: Female, Male
Sex: Female, Male(Participants)CAB LA + RPV LA Q2MDTG + RPVTotal
Female202
Male88795
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CAB LA + RPV LA Q2MDTG + RPVTotal
American Indian or Alaska Native101
Asian-Japanese/East Asian/South East Asian Heritage101
Black or African American21324
White63467
Multiple404
08

Study locations

30 sites
  • GSK Investigational Site
    Phoenix, Arizona 85015, United States
  • GSK Investigational Site
    Bakersfield, California 93301, United States
  • GSK Investigational Site
    Beverly Hills, California 90211, United States
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    Los Angeles, California 90069, United States
  • GSK Investigational Site
    Denver, Colorado 80209, United States
  • GSK Investigational Site
    Washington, District of Columbia 20007, United States
  • GSK Investigational Site
    Washington, District of Columbia 20037, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Fort Pierce, Florida 34982, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33407, United States
  • GSK Investigational Site
    Augusta, Georgia 30912-3130, United States
  • GSK Investigational Site
    Macon, Georgia 31201, United States
  • GSK Investigational Site
    Savannah, Georgia 31401, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Omaha, Nebraska 68198, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89106, United States
  • GSK Investigational Site
    Buffalo, New York 14215, United States
  • GSK Investigational Site
    New York, New York 10032, United States
  • GSK Investigational Site
    New York, New York 10065, United States
  • GSK Investigational Site
    Charleston, South Carolina 29425, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Annandale, Virginia 22003, United States
  • GSK Investigational Site
    Vancouver, British Columbia V6Z 2T1, Canada
  • GSK Investigational Site
    Toronto, Ontario M4N 3M5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1K2, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4E9, Canada
  • GSK Investigational Site
    Montreal, Quebec H3A 1T1, Canada
09

References and documents

Publications

  • Mills A, Richmond GJ, Newman C, Osiyemi O, Cade J, Brinson C, De Vente J, Margolis DA, Sutton KC, Wilches V, Hatch S, Roberts J, McCoig C, Garris C, Vandermeulen K, Spreen WR. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy. AIDS. 2022 Feb 1;36(2):195-203. doi: 10.1097/QAD.0000000000003085. PubMed 34652287 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available, within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided, after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided, for an initial period of 12 months but an extension can be granted, when justified for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Dec 2019, 14 months.

Results were first posted in Jan 2021, 1 year 1 month after primary completion.

Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 14 months is below that.

Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2018
First posted
Aug 21, 2018
StartActual
Sep 24, 2018
Primary completionActual
Dec 11, 2019
CompletionActual
Jan 30, 2023
Results first posted
Jan 15, 2021
Last update
Jun 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03639311
Lead sponsor
ViiV Healthcare
Collaborators
Janssen, LP
Responsible party
Sponsor
First posted
Aug 21, 2018
Start date
Sep 24, 2018
Primary completion
Dec 11, 2019
Completion
Jan 30, 2023
Results posted
Jan 15, 2021
Last update
Jun 11, 2024

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion